[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2777
1. Widera D, Kaus A, Kaltschmidt C, Kaltschmidt B: Neural stem cells, inflammation and NF-kappaB: basic principle of maintenance and repair or origin of brain tumours? J Cell Mol Med; 2008 Apr;12(2):459-70
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although NSCs have beneficial roles, current evidence indicates that brain tumours, such as astrogliomas or ependymomas are also caused by tumour-initiating cells with stem-like properties.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182066.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / NF-kappa B
  • [Number-of-references] 125
  • [Other-IDs] NLM/ PMC3822535
  •  go-up   go-down


2. Knizetova P, Darling JL, Bartek J: Vascular endothelial growth factor in astroglioma stem cell biology and response to therapy. J Cell Mol Med; 2008 Jan-Feb;12(1):111-25
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor in astroglioma stem cell biology and response to therapy.
  • Malignant astrogliomas are among the most aggressive, highly vascular and infiltrating tumours bearing a dismal prognosis, mainly due to their resistance to current radiation treatment and chemotherapy.
  • Efforts to identify and target the mechanisms that underlie astroglioma resistance have recently focused on candidate cancer stem cells, their biological properties, interplay with their local microenvironment or 'niche', and their role in tumour progression and recurrence.
  • Both paracrine and autocrine regulation of astroglioma cell behaviour by locally produced cytokines such as the vascular endothelial growth factor (VEGF) are emerging as key factors that determine astroglioma cell fate.
  • Here, we review these recent rapid advances in astroglioma research, with emphasis on the significance of VEGF in astroglioma stem-like cell biology.
  • Furthermore, we highlight the unique DNA damage checkpoint properties of the CD133-marker-positive astroglioma stem-like cells, discuss their potential involvement in astroglioma radioresistance, and consider the implications of this new knowledge for designing combinatorial, more efficient therapeutic strategies.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / therapy. Brain Neoplasms / metabolism. Brain Neoplasms / therapy. Neoplastic Stem Cells / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18031298.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides; 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 129
  • [Other-IDs] NLM/ PMC3823475
  •  go-up   go-down


3. Banerjee P, Rochford R, Antel J, Canute G, Wrzesinski S, Sieburg M, Feuer G: Proinflammatory cytokine gene induction by human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 Tax in primary human glial cells. J Virol; 2007 Feb;81(4):1690-700
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection with human T-cell leukemia virus type 1 (HTLV-1) can result in the development of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a chronic inflammatory disease of the central nervous system (CNS).
  • We demonstrate that HTLV-1 infection in astrogliomas results in a robust induction of interleukin-1beta (IL-1beta), IL-1alpha, tumor necrosis factor alpha (TNF-alpha), TNF-beta, and IL-6 expression.
  • HTLV encodes for a viral transcriptional transactivator protein named Tax that also induces the transcription of cellular genes.
  • To investigate and compare the effects of Tax1 and Tax2 expression on the dysregulation of proinflammatory cytokines, lentivirus vectors were used to transduce primary human astrocytomas and oligodendrogliomas.
  • The expression of Tax1 in primary human astrocytomas and oligodendrogliomas resulted in significantly higher levels of proinflammatory cytokine gene expression compared to Tax2.
  • Notably, Tax1 expression uniquely sensitized primary human astrocytomas to apoptosis.


Advertisement
4. Komotar RJ, Carson BS, Rao C, Chaffee S, Goldthwaite PT, Tihan T: Pilomyxoid Astrocytoma of the Spinal Cord: Report of Three Cases. Neurosurgery; 2005 Jan 01;56(1):E206-E210

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilomyxoid Astrocytoma of the Spinal Cord: Report of Three Cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184642.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, Pfeifer GP: CpG island hypermethylation in human astrocytomas. Cancer Res; 2010 Apr 1;70(7):2718-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CpG island hypermethylation in human astrocytomas.
  • Astrocytomas are common and lethal human brain tumors.
  • We have analyzed the methylation status of over 28,000 CpG islands and 18,000 promoters in normal human brain and in astrocytomas of various grades using the methylated CpG island recovery assay.
  • In astrocytomas, several hundred CpG islands undergo specific hypermethylation relative to normal brain with 428 methylation peaks common to more than 25% of the tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):761-5 [17151667.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5527-32 [17369352.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):457-66 [17334365.001]
  • [Cites] PLoS Genet. 2007 Oct;3(10):2023-36 [17967063.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):252-7 [18162535.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):358-65 [17653095.001]
  • [Cites] PLoS Biol. 2008 Jan;6(1):e22 [18232738.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12979-84 [18753622.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Methods Mol Biol. 2009;507:65-75 [18987807.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):671-8 [19139413.001]
  • [Cites] Nat Biotechnol. 2009 Apr;27(4):361-8 [19329998.001]
  • [Cites] Epigenetics. 2009 Feb 16;4(2):107-13 [19276669.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):181-7 [19429482.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):188-97 [19429483.001]
  • [Cites] Breast Cancer Res. 2009;11(1):R14 [19250546.001]
  • [Cites] Cancer Cell. 2009 Jun 2;15(6):514-26 [19477430.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Sep;48(9):828-41 [19530241.001]
  • [Cites] Epigenetics. 2009 May 16;4(4):255-64 [19550145.001]
  • [Cites] Clin Cancer Res. 2009 Dec 1;15(23):7124-9 [19934302.001]
  • [Cites] Breast Cancer Res Treat. 2010 Apr;120(2):345-55 [19353266.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Genomics. 2002 Nov;80(5):487-98 [12408966.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):52-9 [12794756.001]
  • [Cites] BMC Cancer. 2004 Sep 14;4:65 [15367334.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2532-4 [9171110.001]
  • [Cites] Mol Biol Evol. 2005 Nov;22(11):2265-74 [16079250.001]
  • [Cites] Cancer Invest. 2006 Feb;24(1):35-40 [16466990.001]
  • [Cites] Cell. 2006 Apr 21;125(2):301-13 [16630818.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6665-74 [16818640.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7490-501 [16885346.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7939-47 [16912168.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8469-76 [16951158.001]
  • [Cites] Nat Genet. 2006 Dec;38(12):1378-85 [17072317.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):157-8 [17200673.001]
  • (PMID = 20233874.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA084469-10A1; United States / NCI NIH HHS / CA / R01 CA084469; United States / NCI NIH HHS / CA / CA084469; United States / NCI NIH HHS / CA / R01 CA084469-10A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS176198; NLM/ PMC2848870
  •  go-up   go-down


6. Khattab AZ, Ahmed MI, Fouad MA, Essa WA: Significance of p53 and CD31 in astrogliomas. Med Oncol; 2009;26(1):86-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of p53 and CD31 in astrogliomas.
  • BACKGROUND: Astrogliomas are the most common primary brain tumor.
  • Its progression is the result of activation of oncogenes, inactivation of tumor suppressor genes (TSGs), and expression of various growth factors.
  • The angiogenesis and p53 in astrogliomas play an important role in its grading, treatment strategies, and hence its clinical outcome.
  • OBJECTIVES: To analyze the frequency of presentation and the possible co-expression of p53 and angiogenesis marker (CD31) and their clinical implications in astrogliomas.
  • MATERIAL AND METHODS: This retrograde study included 45 cases with astrocytomas in the form of paraffin blocks.
  • Sections were stained with hematoxylin and eosin to determine the type and histological grade according to WHO (2007) classification of CNS tumors.
  • RESULTS: Both p53 and CD31 expressions were correlated well with the histopathological grades of different subtypes of astrogliomas with good discrimination between low and high grades.
  • Overall, a highly significant statistical correlation was observed between the grades of astrocytomas and the p53 and CD31 labeling indices.
  • Obviously, these observations demonstrate that the co-expression and increased levels of p53 and CD31 in astrogliomas are increasing as the tumor grade is increasing.
  • Thus, the two markers can be used as adjunct to the diagnosis and stratification of the high grade from the low-grade intrinsic brain astrogliomas.
  • [MeSH-major] Antigens, CD31 / biosynthesis. Astrocytoma / metabolism. Biomarkers, Tumor. Brain Neoplasms / metabolism. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18821037.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


7. Hoffman S, Propp JM, McCarthy BJ: Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol; 2006 Jan;8(1):27-37
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data for the years 1985 through 1999 from six collaborating state cancer registries of the Central Brain Tumor Registry of the United States were used to determine incidence trends in the broad age groups 0-19, 20-64, and >or=65 years, overall and for selected histologies.
  • Specific histologies that were increasing included anaplastic astrocytomas in individuals aged >or=65 years, microscopically confirmed gliomas in both adult age groups, and microscopically confirmed glioma, not otherwise specified (NOS), in children.
  • Decreases were noted for astrocytoma, NOS, nonmicroscopically confirmed gliomas, and pituitary tumors.
  • Improvements in diagnosis and classification are likely reflected in the decreasing trends in unspecified glioma subgroups and the accompanying increasing trends in more specific glioma subgroups.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroepidemiology. 2004 May-Jun;23(3):101-9 [15084778.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):1-11 [16443943.001]
  • [Cites] N Engl J Med. 1985 Oct 3;313(14):859-64 [3897866.001]
  • [Cites] AJR Am J Roentgenol. 1986 Sep;147(3):453-5 [3488645.001]
  • [Cites] J Natl Cancer Inst. 1990 Oct 17;82(20):1621-4 [2213902.001]
  • [Cites] Am J Ind Med. 1991;19(4):421-31 [2035544.001]
  • [Cites] CMAJ. 1991 Dec 15;145(12):1583-91 [1742695.001]
  • [Cites] J Natl Cancer Inst. 1991 Nov 20;83(22):1679-81 [1749021.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1300-6 [1739929.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 18;84(6):442-5 [1538422.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):78-82 [1641113.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):973-9 [7947107.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):330-7 [8001004.001]
  • [Cites] Ann Neurol. 1995 Jan;37(1):67-73 [7818260.001]
  • [Cites] Eur J Cancer. 1994;30A(10):1498-511 [7833109.001]
  • [Cites] IARC Sci Publ. 1994;(128):1-302 [7698823.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1634-42 [8635069.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):532-41 [8697401.001]
  • [Cites] Paediatr Perinat Epidemiol. 1996 Jul;10(3):319-38 [8822774.001]
  • [Cites] Int J Epidemiol. 1995 Dec;24(6):1078-85 [8824847.001]
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • [Cites] Cancer. 2000 May 15;88(10):2342-9 [10820357.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):141-51 [11465394.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):14-25 [11554386.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):257-9 [11958379.001]
  • [Cites] Neurology. 2002 Apr 23;58(8):1304-6 [11971109.001]
  • [Cites] Cancer. 2002 Jul 1;95(1):193-202 [12115333.001]
  • [Cites] J Neurooncol. 2002 Oct;60(1):61-9 [12416547.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Neuroepidemiology. 2003 Mar-Apr;22(2):124-9 [12629278.001]
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):450-5 [14648713.001]
  • [Cites] Neuroepidemiology. 2004 Jan-Apr;23(1-2):85-93 [14739573.001]
  • [Cites] Am J Epidemiol. 2004 Feb 1;159(3):277-83 [14742288.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77 [9731733.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):648-9 [10203289.001]
  • [Cites] AIDS. 1999 Jan 14;13(1):103-8 [10207551.001]
  • [Cites] Cancer. 1999 May 1;85(9):2077-90 [10223251.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):973-4 [10359552.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1382-90 [10451443.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):1141-3 [10496285.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2293-9 [15476282.001]
  • [Cites] Epidemiology. 2004 Nov;15(6):653-9 [15475713.001]
  • (PMID = 16443945.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1871920
  •  go-up   go-down


8. Uno M, Oba-Shinjo SM, Wakamatsu A, Huang N, Avancini Ferreira Alves V, Rosemberg S, Pires de Aguiar PH, Leite C, Miura F, Marino J R, Scaff M, Nagahashi-Marie SK: Association of TP53 mutation, p53 overexpression, and p53 codon 72 polymorphism with susceptibility to apoptosis in adult patients with diffuse astrocytomas. Int J Biol Markers; 2006 Jan - Mar;21(1):50-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of TP53 mutation, p53 overexpression, and p53 codon 72 polymorphism with susceptibility to apoptosis in adult patients with diffuse astrocytomas.
  • : Clarification of TP53 alterations is important to understand the mechanisms underlying the development of diffuse astrocytomas.
  • The aim of this study was to analyze the possible association of TP53 mutation, p53 overexpression, and p53 codon 72 polymorphism with susceptibility to apoptosis in adult Brazilian patients with diffuse astrocytomas.
  • We analyzed 56 surgical specimens of diffuse astrocytomas for alterations of TP53, using polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) direct sequencing. p53 and cleaved caspase 3 protein expression were assessed by immunohistochemistry.
  • We concluded that clarification of the TP53 alterations allows a better understanding of the mechanisms involved in the progression of diffuse astrocytomas, and the allele status at codon 72 was not associated with apoptosis in these tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207094.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


9. Ramonet D, de Yebra L, Fredriksson K, Bernal F, Ribalta T, Mahy N: Similar calcification process in acute and chronic human brain pathologies. J Neurosci Res; 2006 Jan;83(1):147-56
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cellular microcalcification observed in a diversity of human pathologies, such as vascular dementia, Alzheimer's disease, Parkinson's disease, astrogliomas, and posttraumatic epilepsy, also develops in rodent experimental models of central nervous system (CNS) neurodegeneration.
  • This study provides evidence of a common pattern of brain calcification taking place in several human pathologies, and in the rat with glutamate-derived CNS lesions, regarding the chemical composition, physical characteristics, and histological environment of the precipitates.
  • Insofar as calcium precipitation reduces activity signals at no energy expense, the presence in human and rodent cerebral brain lesions of a common pattern of calcification may reflect an imbalance between cellular signals of activity and energy availability for its execution.
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Alzheimer Disease / pathology. Animals. Astrocytoma / pathology. Brain Injuries / complications. Brain Injuries / pathology. Brain Neoplasms / pathology. Calcium / metabolism. Chronic Disease. Dementia, Vascular / pathology. Epilepsy / etiology. Epilepsy / pathology. Female. Humans. Lewy Body Disease / pathology. Male. Mice. Middle Aged. Parkinson Disease / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323208.001).
  • [ISSN] 0360-4012
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] SY7Q814VUP / Calcium
  •  go-up   go-down


10. Zhang XP, Zheng G, Zou L, Liu HL, Hou LH, Zhou P, Yin DD, Zheng QJ, Liang L, Zhang SZ, Feng L, Yao LB, Yang AG, Han H, Chen JY: Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Mol Cell Biochem; 2008 Jan;307(1-2):101-8
Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells.
  • In this study, we accessed potential functions of the Notch pathway in the formation of cancer stem cells using human glioma.
  • Using RT-PCR, we found that most human astrogliomas of different grades expressed moderate to high level of Notch receptors and ligands. mRNA of Hes5 but not Hes1, both of which are major downstream molecules of the Notch pathway, was also detected.
  • In human glioma cell lines BT325, U251, SHG-44, and U87, mRNA encoding different types of Notch receptors were detected, but active form of Notch1 (NIC) was only detected in SHG-44 and U87 by Western blot.
  • Interestingly, proliferation of these two glioma cell lines appeared faster than that of the other two lines in which NIC was not detected.
  • We have over-expressed NIC of Notch1 in SHG-44 cells by constitutive transfection to evaluate the effects of Notch signaling on glioma cells.
  • These data suggest that Notch signaling promote the formation of cancer stem cell-like cells in human glioma.
  • [MeSH-major] Cell Proliferation. Glioma / pathology. Neoplastic Stem Cells / pathology. Neurons / pathology. Receptors, Notch / genetics. Receptors, Notch / physiology
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Humans. Protein Structure, Tertiary / genetics. Signal Transduction. Stem Cells / metabolism. Stem Cells / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17849174.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Notch
  •  go-up   go-down


11. Geiger KD, Stoldt P, Schlote W, Derouiche A: Ezrin immunoreactivity reveals specific astrocyte activation in cerebral HIV. J Neuropathol Exp Neurol; 2006 Jan;65(1):87-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The actin-binding protein ezrin is associated with cellular shape changes, motility, tumor invasion, and lymphocyte activation.
  • We have earlier shown that ezrin immunoreactivity (IR) is faintly present in normal astrocytes but increased in malignant human astrogliomas.
  • Semiquantitative ezrin-IR was compared with the common glial markers GFAP, ferritin, and HLA-DR in relation to clinical and morphologic criteria of HIV encephalopathy.
  • Combined ezrin-IR and GFAP-IR thus reveals 2 distinct states of astrocytic activation.
  • Ezrin-IR might also provide a diagnostic tool for the classification of HIV encephalopathy.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410752.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / Glial Fibrillary Acidic Protein; 0 / HLA-DR Antigens; 0 / ezrin; 9007-73-2 / Ferritins
  •  go-up   go-down


12. Stupp R, Reni M, Gatta G, Mazza E, Vecht C: Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol; 2007 Jul;63(1):72-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma in adults.
  • Anaplastic astrocytoma is an uncommon disease in the adult population.
  • Based on randomized data available, chemotherapy has consistently failed to improve the outcome of patients with anaplastic astrocytoma, while a meta-analysis showed a small, but significant improvement in survival favouring the use of chemotherapy.
  • In recurrent disease, chemotherapy with temozolomide has been proven to be active and well-tolerated in phase II trials, but no comparative phase III trials of other cytotoxic drugs have been conducted.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. Clinical Trials, Phase II as Topic. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Prognosis. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for anaplastic astrocytoma .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17478095.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 69
  •  go-up   go-down


13. Rudnick JD, Phuphanich S, Chu R, Mazer M, Wang H, Serrano N, Francisco M, Black KL, Wheeler C, Yu J: A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. J Clin Oncol; 2009 May 20;27(15_suppl):2033

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
  • : 2033 Background: Our prior immunotherapy trials demonstrated efficacy in generating a tumor specific immune response in malignant glioma and the potential for high tumor-specific toxicity and sustained tumoricidal activity.
  • METHODS: We exploited this synergistic effect to maintain a cytotoxic environment around the tumor milieu.
  • Patients with high-grade glioma were eligible after maximal resection with biodegradable carmustine (BCNU) wafer placement.
  • Screening leukapheresis is used to isolate mononuclear cells which are differentiated into dendritic cells, pulsed with tumor lysate, and then 3 intradermal vaccines are administered at 2-week intervals.
  • The histology included 3 newly diagnosed glioblastoma multiforme (GBM), 8 recurrent GBM, 2 newly diagnosed anaplastic astrocytoma (AA), and 2 recurrent AA.
  • A stable disease interval of 13 to 90 weeks was observed for patients who received vaccine.
  • The 3 newly diagnosed GBM patients have stable disease (18 to 71 weeks).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964627.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Ochsenbein AF, Schubert AD, Vassella E, Mariani L: Quantitative analysis of 0<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):2069

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of 0<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
  • : 2069 Background: Loss of heterozygosity (LOH) on the chromosomes 1p and 19q is associated with sensitivity to alkylating agents like temozolomide (TMZ) in patients with low-grade gliomas; whether methylation of the MGMT-promoter, a predictive factor in glioblastoma patients, also correlates with tumor response to TMZ in low-grade gliomas is unclear.
  • METHODS: We performed a retrospective analysis of patients with histologically verified low-grade gliomas (WHO Grade II) who were treated with TMZ for tumor progression at our hospital between November 1999 and November 2007.
  • Objective tumor response was assessed by MRI at 6-month intervals.
  • LOH of microsatellite markers on chromosomes 1p and 19q was determined by polymerase chain reaction (PCR) amplification of the matched pairs of blood and tumor DNA.
  • Seven patients had prior surgical resection of the tumor.
  • Histological classification revealed 10 oligodendrogliomas, 7 oligoastrocytomas, and 5 astrocytomas.
  • CONCLUSIONS: Quantitative methylation-specific PCR of the MGMT promoter correlates with radiological response to chemotherapy with temozolomide in WHO grade II gliomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964685.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Herndon J 2nd, Vredenburgh J, Reardon D, Desjardins A, Peters K, Gururangan S, Norfleet J, Friedman A, Bigner D, Friedman HS: Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas.
  • : e13016 Background: Recurrent malignant gliomas have a poor prognosis, with a median survival of 6-15 months, with grade 4 glioblastomas more aggressive than grade 3 anaplastic astrocytomas or oligodendrogliomas.
  • Vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) are critically important in glioma biology.
  • We report a phase I trial of vandetanib in combination with oral etoposide for recurrent malignant glioma.
  • METHODS: Patients with histologically documented recurrent grade 3 or grade 4 malignant glioma were eligible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962830.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Merrell RT, Lachance DH, Anderson SK: Seizures in patients with glioma treated with phenytoin and levetiracetam. J Clin Oncol; 2009 May 20;27(15_suppl):e13020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seizures in patients with glioma treated with phenytoin and levetiracetam.
  • : e13020 Background: Seizures are common in patients with glioma.
  • We compare seizure outcomes and side effects in patients with glioma treated with phenytoin and levetiracetam monotherapy.
  • METHODS: Retrospective analysis of consecutive patients with glioma.
  • RESULTS: 76 patients (34 female) with pathologically proven glioma and seizures were identified, 25 treated with phenytoin and 51 with levetiracetam.
  • 64% had grade 4 astrocytoma.
  • When adjusting for age, gender, type of seizure, type of glioma, and dosage using univariate and multivariate models there were no differences between the treatment groups and none of these covariates were statistically significant for explaining the second seizure rates between treatment groups (all p values >0.05).
  • CONCLUSIONS: In this study, glioma patients treated with levetiracetam had similar seizure control as patients treated with phenytoin.
  • Levetiracetam is a safe, effective, and preferred alternative for seizure management in patients with glioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962817.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Potthast L, Chowdhary S, Pan E, Yu D, Zhu W, Brem S: The infiltrative, diffuse pattern of recurrence in patients with malignant gliomas treated with bevacizumab. J Clin Oncol; 2009 May 20;27(15_suppl):2057

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The infiltrative, diffuse pattern of recurrence in patients with malignant gliomas treated with bevacizumab.
  • : 2057 Background: There is no standard of care for recurrent gliomas; however, bevacizumab is often used as a salvage chemotherapy regimen.
  • A diffuse, infiltrative pattern of recurrence, as evidenced by MR imaging, was seen manifesting as multifocal disease or presumed CSF dissemination with subependymal spread.
  • METHODS: We conducted a retrospective analysis of 40 recurrent glioma patients followed at Moffitt Cancer Center from September 2006 through December 2008 treated with bevacizumab alone or in combination with irinotecan.
  • Histologies included glioblastoma (GB), anaplastic astrocytomas (AA), anaplastic oligodendrogliomas (AO), anaplastic oligoastrocytomas (AOA), and low-grade astrocytomas.
  • CONCLUSIONS: There appears to be an increase in a diffuse, infiltrative pattern of recurrence among recurrent glioma patients treated with bevacizumab as a salvage regimen.
  • It is unclear why the disparity among this subset of patients occurs, however, we hypothesize that this may once again highlight the distinct tumor biology among young glioma patients.
  • The impact of this observation on clinical decision making on whether to utilize bevacizumab in young recurrent glioma patients warrants further investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964663.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Lin Y, Jiang T, Li G: MGMT expression in low-grade gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT expression in low-grade gliomas.
  • : e13001 Background: To evaluate the expression of MGMT in low-grade gliomas, and explore the relationship between its expression and the histological type of the tumour and the corresponding MRI characteristics.
  • METHODS: We assessed 389 low-grade gliomas (182 astrocytomas, 145 oligoastrocytomas, 61 oligodendrocytomas) with immunohistochemistry staining.
  • We also recorded the preoperational MRI criteria such as tumor volume on T2 image, enhancing volume, tumor location, and relationship with ventricles.
  • RESULTS: The expression of MGMT in astrocytomas, oligoastrocytomas, and oligocytomas were 1.67 ± 0.78, 1.41 ± 0.86,1.44 ± 0.78, respectively.
  • Significant stronger expression of MGMT was observed in astrocytomas than oligoastrocytomas and oligodendrocytomas (t = 3.00, p = 0.03), but no significant difference was observed between the latter two (t = 0.28, p = 0.78).
  • MGMT expression level was significantly correlated with the enhancing volume of the tumor (r = -0.605, p = 0.002), but did not correlate with the total tumor volume (p = 0.504).
  • This suggest that MGMT may contribute to the tumor resistance to radiotherapy and chemotherapy in low-grade gliomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962757.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Witt H, Korshunov A, Remke M, Janzarik WG, Gnekow A, Scheurlen W, Kulozik AE, Lichter P, Pfister S: DNA methylation pattern of brain stem pilocytic astrocytomas in children. J Clin Oncol; 2009 May 20;27(15_suppl):10021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation pattern of brain stem pilocytic astrocytomas in children.
  • : 10021 Background: Pilocytic astrocytoma (WHO grade I) comprises the most frequent brain tumor in childhood.
  • METHODS: To identify novel genes involved in astrocytoma pathogenesis, we performed a genome-wide DNA methylation analysis of 78 pilocytic astrocytoma samples from different tumor locations (diencephalic, cerebral, cerebellar, brain stem).
  • Two CpG sites were analyzed for each of a total of 14.000 promoters per sample.
  • Moreover, from 14 tumors clustering together with the brain stem tumors, 5 patients experienced disease recurrence (38%) as opposed to 20% in the remaining group.
  • Genes contained in the signature most interestingly included three homeobox family genes (HOXB1, HOXD3, and HOXD4), and NES, a tumor stem cell marker.
  • CONCLUSIONS: These data suggest that brain stem pilocytic astrocytomas display biologic features different from most tumors of other locations and share a methylation signature with tumors prone to disease recurrence from other locations.
  • We provide first evidence for a role of differentially methylated homeobox family genes in the pathogenesis of pilocytic astrocytoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Desjardins A, Reardon DA, Gururangan S, Peters K, Threatt S, Friedman A, Friedman H, Vredenburgh J: Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG). J Clin Oncol; 2009 May 20;27(15_suppl):e13004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG).
  • METHODS: Eligibility included: adult patients with stable or recurrent MG (GBM, anaplastic astrocytoma [AA], anaplastic oligodendroglioma [AO]) previously treated with radiation therapy (RT) and with or without chemotherapy; interval of at least two weeks between prior RT, or four weeks between prior chemotherapy; Karnofsky ≥ 60%; and adequate hematologic, renal and liver function.
  • Radiographic evaluation reported: 2 partial responses, 14 stable disease for at least 4 cycles, and 11 disease progression after either the first or second cycle.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962751.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Karrasch M, Gillespie GY, Braz E, Liechty PG, Nabors LB, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Markert JM: Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results. J Clin Oncol; 2009 May 20;27(15_suppl):2042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results.
  • Safety and efficacy of intracerebral inoculations of G207 to patients suffering from recurrent malignant gliomas have been demonstrated in previous clinical trials.
  • METHODS: In this phase I clinical trial, a total of 1 x 10<sup>9</sup> plaque forming units (pfu) G207 were administered by five stereotactic injections of 0.2 mL each into regions of recurrent malignant glioma defined by MRI, followed by focal radiation therapy 24 hours post injection.
  • Included patients suffered from inoperable pathologically proven recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA) which was progressive despite radiotherapy or chemotherapy and failed external beam radiotherapy > 5 Gray prior to study enrolment.
  • The 2 patients with initial PR (1xGBM, 1xAA) were re-treated with G207/Irradiation at time point of tumor recurrence, showing PR one month after re-treatment again.
  • Within persistent areas of tumor, HSV staining was present by using a polyclonal antibody for HSV, indicating intratumoral G207 replication (proof of concept).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964649.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Simonelli M, Banna G, Navarria P, Di Ieva A, Zucali P, De Vincenzo F, Gaetani P, Condorelli R, Rodriguez Y Baena R, Scorsetti M, Santoro A: Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas.
  • : e13037 Background: Anaplastic astrocytoma (AA), oligodendroglioma (AOD), and oligoastrocytoma (AOA) are rare tumors showing variable outcome due to their histological heterogeneity and different chemo- and radio-sensitivity.
  • Currently, the addition of chemotherapy to radiotherapy (RT) for newly diagnosed anaplastic gliomas is not sustained by available data.
  • We evaluated the addition of temozolomide (TMZ) to radiotherapy for newly diagnosed anaplastic gliomas in terms of tolerability, progression-free survival (PFS), and overall survival (OS).
  • METHODS: Since September 2004, following initial surgery, patients (pts) with histologically confirmed anaplastic glioma, Karnofsky Performance Status (KPS) ≥40, adequate organ function, no prior chemotherapy, were treated with RT to limited fields once daily at 2 Gy per fraction, 5 days a week, for a total of 60 Gy with concomitant TMZ (75 mg/m<sup>2</sup> for 7 days a week) followed by 6 cycles of maintenance TMZ at 200 mg/m<sup>2</sup> on days 1-5 every 28 days.
  • Nine pts (32%) underwent tumor complete resection, 10 partial resection (36%), and 9 (32%) tumor biopsy.
  • CONCLUSIONS: The addition of temozolomide to radiation therapy for newly diagnosed anaplastic gliomas is well tolerated and seems active; efficacy needs confirmation in a randomized clinical trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962859.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Abacioglu MU, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M: Efficacy of protracted dose-dense temozolomide (TMZ) in patients with progressive high-grade glioma. J Clin Oncol; 2009 May 20;27(15_suppl):e13018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of protracted dose-dense temozolomide (TMZ) in patients with progressive high-grade glioma.
  • : e13018 Background: The study was aimed to evaluate the efficacy of TMZ on a protracted dose-dense schedule after standard 5-day TMZ regimen in patients with progressive high-grade glioma.
  • METHODS: In this phase II prospective study, patients who had progression on standard 5-day TMZ for recurrence (group 1) or recurrence after concurrent radiotherapy+TMZ and ≥ 2 cycles of adjuvant TMZ (group 2) for high-grade glioma received TMZ 100 mg/m2× 21 q28 days until progression according to MacDonald's criteria.
  • The histopathology was glioblastoma in 18 and grade 3 glioma (anaplastic astrocytoma, anaplastic oligoastrocytoma or anaplastic oligodendroglioma) in 7.
  • The best response during treatment was partial response in 2 (8%), stable disease in 9 (36%), and progression in 9 (36%) out of 20 patients assessed.
  • CONCLUSIONS: Protracted dose-dense TMZ after 5-day schedule for recurrent or progressive disease has modest efficacy with tolerable toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962826.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Lassman AB, Oligodendroglioma Study Group: Retrospective analysis of outcomes among more than 1,000 patients with newly diagnosed anaplastic oligodendroglial tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We retrospectively identified adults with newly diagnosed anaplastic oligodendroglioma (AO) or oligo-astrocytoma (AOA) seen at 17 medical centers from 1981-2007 exclusive of phase III or bone marrow transplant trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964586.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Franceschi E, Tosoni A, Ermani M, Spagnolli F, La Torre L, Galzio RJ, Pozzati E, Talacchi A, Benevento F, Brandes AA: Impact of MGMT methylation status on 1p/19q intact anaplastic gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of MGMT methylation status on 1p/19q intact anaplastic gliomas.
  • : e13003 Background: Chromosomes 1p/19q codeletion has been recognized as a prognostic and predictive factor in patients (pts) with grade 3 gliomas.
  • Non-codeleted (intact) anaplastic oligodendroglioma showed a survival comparable to that usually observed in pts with anaplastic astrocytomas; MGMT methylation status, moreover, has been found to be a prognostic factor in glioblastoma and anaplastic gliomas (AG).
  • Histology was anaplastic oligodendroglioma in 17 pts, anaplastic oligoastrocytoma in 20 pts, and anaplastic astrocytoma in 30 pts; all these pts were 1p19q intact and received surgery, RT, and CT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962754.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Tosoni A, Franceschi E, Ermani M, Bacci A, Volpin L, Lombardo L, Ravenna G, Pinna G, Poggi R, Brandes AA: MGMT methylation status as a prognostic factor in anaplastic astrocytomas. J Clin Oncol; 2009 May 20;27(15_suppl):2052

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT methylation status as a prognostic factor in anaplastic astrocytomas.
  • However, further data on the epigenetic feature are needed before its role in rare diseases such as anaplastic astrocytomas (AA) can be established.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964674.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Johnson MW, Eberhart CG, Perry A, Tihan T, Cohen KJ, Rosenblum MK, Rais-Bahrami S, Goldthwaite P, Burger PC: Spectrum of pilomyxoid astrocytomas: intermediate pilomyxoid tumors. Am J Surg Pathol; 2010 Dec;34(12):1783-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of pilomyxoid astrocytomas: intermediate pilomyxoid tumors.
  • To define the spectrum of pilomyxoid morphology and to characterize the association between pilomyxoid astrocytoma (PMA) and pilocytic astrocytoma (PA), 84 cases of pediatric astrocytomas with pilomyxoid features were reviewed.
  • Both the existence of intermediate tumors and the finding that some PMAs and intermediate tumors mature into PA-like neoplasms over time, provided strong support for a biological relationship between PMA and PA.
  • Additional evidence for a "maturational effect" was the finding that intermediate tumors occurred in patients with a median age of 36 months compared with the median age of 21 months for those with PMAs (P=0.017).
  • Features that were often assumed to be poor prognostic indicators in gliomas, that is, necrosis, mitotic figures, and vascular proliferation, were not uncommon in typical PMAs and intermediate lesions.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Spinal Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Child. Child, Preschool. Female. Humans. Male. Mitosis. Necrosis. Neoplasm Recurrence, Local. Neovascularization, Pathologic. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21107083.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


28. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C: Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol; 2009 Sep;118(3):401-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
  • Separation of pilocytic astrocytoma from diffuse astrocytomas frequently poses problems mostly related to small sample size.
  • Precise classification and grading are essential due to different therapeutic strategies prompted by diagnoses of pilocytic astrocytoma WHO grade I, diffuse astrocytomas WHO grade II or anaplastic astrocytoma WHO grade III.
  • Recently, genomic aberrations with a high specificity for distinct glioma entities have been described.
  • Pilocytic astrocytomas carry a duplication at chromosome band 7q34 containing a BRAF-KIAA1549 gene fusion in the majority of cases.
  • IDH1 mutations are observed very frequently in adult astrocytomas and IDH2 mutations have been reported in some astrocytomas.
  • We examined a series of 120 astrocytomas including 70 pilocytic astrocytomas WHO grade I and 50 diffuse astrocytomas WHO grade II for both, BRAF-KIAA1549 fusion with a newly developed FISH assay and mutations in IDH1 and IDH2 by direct sequencing.
  • Pilocytic astrocytomas contained the BRAF fusion in 49 cases (70%) but neither IDH1 nor IDH2 mutations.
  • Astrocytomas WHO grade II exhibited IDH1 mutations in 38 cases (76%) but neither IDH2 mutations nor BRAF fusions.
  • Thus, combined molecular analysis of BRAF and IDH1 is a sensitive and highly specific approach to separate pilocytic astrocytoma from diffuse astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Isocitrate Dehydrogenase / genetics. Proto-Oncogene Proteins B-raf / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Tissue Array Analysis


29. Shin E, Ki Chung C, Park SH: Granular cell astrocytoma. Pathol Res Pract; 2007;203(1):57-62
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell astrocytoma.
  • Granular cell astrocytoma (GCA) is a rare morphologic variant of astrocytomas, characterized by a prominent component of plump granular tumor cells.
  • It has an aggressive clinical course as compared with conventional astrocytoma of the same grade.
  • As its cytologic feature resembles that of a foamy histiocyte and, histologically, the tumor is rich in arborizing capillaries, it can be difficult to distinguish GCA from non-neoplastic diseases such as infarct or demyelinating disease.
  • In this paper, a case of a GCA in a 28-year-old full-term pregnant woman suffering from a sudden episode of seizure during delivery is described, focusing on histopathological, immunohistochemical, and ultrastructural features.
  • Histopathology and immunohistochemical phenotype of this tumor were identical to the previous reports.
  • Ultrastructurally, secondary lysosome (so-called lipofuscin bodies) granules were present but not numerous; instead, many mitochondria and unusual paracrystalline inclusions were found in each tumor cell.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Inclusion Bodies / ultrastructure. Lipofuscin. Lysosomes / ultrastructure. Microscopy, Electron, Transmission. Mitochondria / ultrastructure. Pregnancy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197117.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lipofuscin
  •  go-up   go-down


30. Grujicic M, Vuckovic N, Vulekovic P, Novakovic B: The basic morphological characteristics of astrocytomas in Vojvodina in the period 2001-2006. J BUON; 2009 Oct-Dec;14(4):625-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The basic morphological characteristics of astrocytomas in Vojvodina in the period 2001-2006.
  • PURPOSE: Astrocytomas are the most common primary intracranial neoplasms.
  • The aim of this investigation was to register the age, sex, tumor localization, frequency and histological types of patients with astrocytomas.
  • Tumor histological studies were carried out in the Laboratory of the Centre for Pathology and Histology of the Clinical Centre of Vojvodina.
  • Out of 490 patients with diagnosed intracranial tumors, 139 (28.4%) had astrocytomas.
  • RESULTS: Astrocytomas were more frequent in males (63.3%) and were most common in the 50-59-year age group (39.5%).
  • In regard to other histological types of intracranial tumors, astrocytomas were more frequent in males (34.8%).
  • Grade III astrocytomas were most common (55.4%).
  • The frequency of hemorrhage and thrombosis showed a positive correlation with the histological grade of astrocytomas.
  • CONCLUSION: The typical patient with astrocytoma is a male of 50-59 years.
  • The tumor is grade III located in the right frontal region.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Sex Factors. Yugoslavia

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148453.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


31. Ranza E, Bertolotti A, Facoetti A, Mariotti L, Pasi F, Ottolenghi A, Nano R: Influence of imatinib mesylate on radiosensitivity of astrocytoma cells. Anticancer Res; 2009 Nov;29(11):4575-8
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of imatinib mesylate on radiosensitivity of astrocytoma cells.
  • The objective of this study was to determine whether gamma radiation could sensitize astrocytoma cell lines to the effects of imatinib in vitro.
  • For this purpose, T98G and MOG-G-UVW astrocytoma cells were treated with imatinib alone or in combination with gamma radiation.
  • [MeSH-major] Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Piperazines / pharmacology. Pyrimidines / pharmacology
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Benzamides. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / radiation effects. Combined Modality Therapy. Dose-Response Relationship, Drug. Gamma Rays. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans. Imatinib Mesylate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032406.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


32. Lueth M, Wronski L, Giese A, Kirschner-Schwabe R, Pietsch T, von Deimling A, Henze G, Kurtz A, Driever PH: Somatic mitochondrial mutations in pilocytic astrocytoma. Cancer Genet Cytogenet; 2009 Jul;192(1):30-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mitochondrial mutations in pilocytic astrocytoma.
  • The most common brain tumors in childhood and adolescence are low grade pilocytic astrocytomas (PA).
  • Sequencing analysis of the complete mitochondrial genome of tumor tissue and corresponding blood samples from 19 patients with PA was performed.
  • The PA tumors were found to have the highest percentage of mitochondrial mutations of any of the neuroectodermal tumor entities studied to date.
  • To reveal the prognostic importance of these mutations in the tumor biology of PA, larger series need to be studied prospectively.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Genome, Mitochondrial. Mutation


33. Cohen VM, Shields CL, Furuta M, Shields JA: Vitreous seeding from retinal astrocytoma in three cases. Retina; 2008 Jun;28(6):884-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitreous seeding from retinal astrocytoma in three cases.
  • PURPOSE: To report three cases of vitreous seeding from retinal astrocytoma.
  • RESULTS: An asymptomatic 8-year-old boy (Case 1) presented with a white juxtapapillary retinal tumor and extensive overlying large vitreous seeds.
  • Fine-needle aspiration biopsy (FNAB) confirmed the diagnosis of benign retinal astrocytoma.
  • A 5-year-old boy (Case 2) presented with a large, multilobulated, tan juxtapapillary retinal tumor.
  • FNAB revealed cells of astrocytic origin.
  • Histopathologic analysis of the enucleated globe supported the diagnosis of retinal astrocytoma.
  • FNAB revealed cells of astrocytic origin.
  • The tumor height increased from 2.5 mm to 5.5 mm, and total retinal detachment developed.
  • After enucleation, the diagnosis of retinal astrocytoma was confirmed.
  • CONCLUSIONS: Retinal astrocytoma can produce vitreous seeds, sometimes associated with tumor growth.
  • [MeSH-major] Astrocytoma / secondary. Eye Neoplasms / secondary. Neoplasm Seeding. Retinal Neoplasms / pathology. Vitreous Body / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18536607.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Mendiratta-Lala M, Kader Ellika S, Gutierrez JA, Patel SC, Jain R: Spinal cord pilomyxoid astrocytoma: an unusual tumor. J Neuroimaging; 2007 Oct;17(4):371-4
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord pilomyxoid astrocytoma: an unusual tumor.
  • We present the imaging findings of a case of spinal pilomyxoid astrocytoma in a 29-year-old woman with history of neck and back pain and weakness of bilateral upper extremities.
  • Spinal pilomyxoid astrocytoma is rare with only three reported cases in pediatric population in the literature.
  • This report illustrates the MR findings of an unusual case of intradural extramedullary spinal pilomyxoid tumor in an adult patient.
  • [MeSH-major] Astrocytoma / diagnosis. Magnetic Resonance Imaging. Myxoma / diagnosis. Spinal Cord Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17894633.001).
  • [ISSN] 1051-2284
  • [Journal-full-title] Journal of neuroimaging : official journal of the American Society of Neuroimaging
  • [ISO-abbreviation] J Neuroimaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


35. Canesso A, Gardiman M, Salmaso R, Alaggio R, Ninfo V: An unusual case of malignant pilocytic astrocytoma occurring in the eye. Virchows Arch; 2006 Aug;449(2):248-52
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of malignant pilocytic astrocytoma occurring in the eye.
  • Pilocytic astrocytoma is a central nervous system neoplasia that arises during pediatric age.
  • It is a low-grade lesion that can rarely undergo malignant changes presenting the histologic features of a high-grade glioma.
  • We report a case of a pilocytic astrocytoma arising in the eyeball of a 53-year-old man affected by glaucoma that underwent malignant evolution.
  • [MeSH-major] Astrocytoma / pathology. Eye Neoplasms / pathology

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16715230.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Naidoo V, Naidoo S, Mahabeer R, Raidoo DM: Localization of the endothelin system in human diffuse astrocytomas. Cancer; 2005 Sep 1;104(5):1049-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of the endothelin system in human diffuse astrocytomas.
  • Because only immunoreactive ET-1 has been observed within human astrocytic tumor cells, the authors investigated the localization of the entire ET-1 system (ET-1 mRNA, ET-1, ECE-1, ETA and ETB receptors) in surgical samples of human diffuse astrocytomas WHO Grade II (n = 6).
  • RESULTS: All ET components were detected in the six tumor samples.
  • Intense (3+) cytoplasmic ET-1 mRNA labeling was observed in more than 75% of cells in all 6 astrocytomas.
  • Up to 75% of tumor cells displayed intense ET-1 and ECE-1 immunolabeling distributed throughout their cytoplasm.
  • Immunoreactive ETA and ETB receptors, observed in 25% to 75% of astrocytic tumor cells, were of moderate intensity.
  • In addition, all components of the ET system were seen within endothelial cells of tumor blood vessels.
  • CONCLUSIONS: The presence of ET-1 mRNA, ECE-1, and ET-1 within tumor astrocytes suggests local ET synthesis and processing.
  • [MeSH-major] Aspartic Acid Endopeptidases / analysis. Astrocytoma / chemistry. Endothelin-1 / analysis. Metalloendopeptidases / analysis. Receptor, Endothelin A / analysis. Receptor, Endothelin B / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007684.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / RNA, Messenger; 0 / Receptor, Endothelin A; 0 / Receptor, Endothelin B; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.71 / endothelin-converting enzyme
  •  go-up   go-down


37. Dorward IG, Luo J, Perry A, Gutmann DH, Mansur DB, Rubin JB, Leonard JR: Postoperative imaging surveillance in pediatric pilocytic astrocytomas. J Neurosurg Pediatr; 2010 Oct;6(4):346-52
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative imaging surveillance in pediatric pilocytic astrocytomas.
  • OBJECT: Currently there is no consensus regarding the frequency of neuroimaging following gross-total resection (GTR) of pilocytic astrocytoma (PA) in children.
  • The classification of GTR was based on a lack of nodular enhancement on early postoperative MR imaging.
  • RESULTS: Of 13 patients demonstrating new nodular enhancement on MR imaging at 3-6 months, the disease progressed in 10, with a median time to recurrence of 6.4 months (range 2-48.2 months).
  • At last follow-up, 29 patients had no recurrence, whereas in 1 additional patient the tumor recurred at 48 months, despite the absence of a new contrast-enhancing nodule at 3-6 months (for a total of 11 patients with recurrence).
  • CONCLUSIONS: Surveillance MR imaging at 3-6 months after resection predicts tumor recurrence following GTR.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / pathology. Postoperative Complications / pathology
  • [MeSH-minor] Adolescent. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Biopsy. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Microglia / metabolism. Microglia / pathology. Predictive Value of Tests. Risk Factors. Young Adult

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20887107.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human
  •  go-up   go-down


38. Zhi F, Chen X, Wang S, Xia X, Shi Y, Guan W, Shao N, Qu H, Yang C, Zhang Y, Wang Q, Wang R, Zen K, Zhang CY, Zhang J, Yang Y: The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer; 2010 Jun;46(9):1640-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma.
  • BACKGROUND: The aberrant expression of microRNAs (miRNAs) is associated with a variety of diseases including cancers.
  • In the present study, the miRNA expression profile was examined in astrocytoma, a malignant and prevalent intracranial tumour in adults.
  • METHODS: We screened the expression profile of 200 miRNAs in a training sample set consisting of 84 astrocytoma samples and 20 normal adjacent tissue (NAT) samples using the method of stem-loop quantitative RT-PCR.
  • The significantly altered miRNAs were validated in another independent sample set consisting of 40 astrocytoma samples and 40 NAT samples.
  • The correlation of the miRNA levels with survival in astrocytoma samples was estimated by performing Kaplan-Meier survival analysis and univariate/multivariate Cox proportional hazard regression analysis.
  • RESULTS: After a two-phase selection and validation process, seven miRNAs were found to have a significantly different expression profile in astrocytoma samples upon comparison to the NAT samples.
  • The down-regulation of hsa-miR-137 in astrocytomas was shown to be associated with advanced clinical stages of this disease.
  • CONCLUSIONS: Our results suggest a great potential for the use of miRNA profiling as a powerful diagnostic and prognostic marker in defining the signature of astrocytomas and in predicting the post-surgical outcome.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. MicroRNAs / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20219352.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN106 microRNA, human; 0 / MIRN21 microRNA, human; 0 / MIrn181 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


39. Jeong SM, Chung YG, Lee JB, Shin IY: Intracranial dissemination from spinal cord anaplastic astrocytoma. J Korean Neurosurg Soc; 2010 Jan;47(1):68-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial dissemination from spinal cord anaplastic astrocytoma.
  • We report a case of intracranial dissemination developing approximately 4 months after partial removal of a spinal cord anplastic astrocytoma in a 22-year-old male.
  • The tumor was partially removed.
  • The final histologic diagnosis was anaplastic astrocytoma.
  • He underwent computed tomography-guided stereotactic biopsy and histological appearance was consistent with anaplastic astrocytoma.
  • The clinical course indicates that the tumor originated in the spinal cord and extended into the subarachnoid space, first the spinal canal and later intracranial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropathology. 2006 Dec;26(6):519-27 [17203587.001]
  • [Cites] Pathol Oncol Res. 2006;12(3):143-7 [16998593.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):211-6 [16552620.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 May;32(5):281-4 [1378944.001]
  • [Cites] Surg Neurol. 2001 Jul;56(1):39-41 [11546571.001]
  • [Cites] Rinsho Hoshasen. 1989 Feb;34(2):249-52 [2754823.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):50-4 [2909688.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):295-300 [3392575.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Jul;30(7):489-94 [1701860.001]
  • (PMID = 20157383.001).
  • [ISSN] 1598-7876
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2817520
  • [Keywords] NOTNLM ; Anaplastic astrocytoma / Intracranial dissemination / Spinal cord
  •  go-up   go-down


40. Alimohamadi M, Bidabadi MS, Ayan Z, Ketabchi E, Amirjamshidi A: Pilomyxoid astrocytoma with involvement of the sella turcica in an adolescent. J Clin Neurosci; 2009 Dec;16(12):1648-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilomyxoid astrocytoma with involvement of the sella turcica in an adolescent.
  • Pilomyxoid astrocytoma (PMA) is a recently described tumor typically occurring in the hypothalamic-chiasmatic region of very young children.
  • PMA is characterized by a more aggressive course than pilocytic astrocytoma and exhibits certain differing histological features.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Sella Turcica / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766001.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


41. Zuzak TJ, Poretti A, Drexel B, Zehnder D, Boltshauser E, Grotzer MA: Outcome of children with low-grade cerebellar astrocytoma: long-term complications and quality of life. Childs Nerv Syst; 2008 Dec;24(12):1447-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of children with low-grade cerebellar astrocytoma: long-term complications and quality of life.
  • OBJECTS: To study the long-term outcome of surgically treated low-grade cerebellar astrocytomas in children.
  • In 21 of 31 survivors (median follow-up time 7.9 years; range 5.6-27.4 years) who agreed to participate, tumor control, neurological and cognitive complications, and their impact on behavioral and emotional adjustment and health-related quality of life (HRQoL) were comprehensively assessed qualitatively and quantitatively.
  • CONCLUSION: Childhood low-grade cerebellar astrocytomas have an excellent cure rate by tumor surgery alone.
  • [MeSH-major] Astrocytoma / surgery. Cerebellar Neoplasms / surgery. Quality of Life
  • [MeSH-minor] Activities of Daily Living. Child. Cognition Disorders / diagnosis. Cognition Disorders / etiology. Disease-Free Survival. Follow-Up Studies. Health Status Indicators. Humans. Postoperative Complications / diagnosis. Postoperative Complications / etiology. Survivors. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18690461.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Roncadin C, Dennis M, Greenberg ML, Spiegler BJ: Adverse medical events associated with childhood cerebellar astrocytomas and medulloblastomas: natural history and relation to very long-term neurobehavioral outcome. Childs Nerv Syst; 2008 Sep;24(9):995-1002; discussion 1003
MedlinePlus Health Information. consumer health - Mental Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adverse medical events associated with childhood cerebellar astrocytomas and medulloblastomas: natural history and relation to very long-term neurobehavioral outcome.
  • OBJECTIVES: The objectives of the study are to document the incidence of medical events in survivors of childhood posterior fossa astrocytoma or medulloblastoma in four time periods (diagnosis, perioperative, short-term survival, long-term survival), and to study whether medical events predict neurobehavioral outcome.
  • MATERIALS AND METHODS: Twenty-nine astrocytoma and 29 medulloblastoma survivors were studied at least 5 years post-diagnosis.
  • In the astrocytoma group, poorer long-term neurobehavioral outcome was associated with more adverse medical events in the perioperative and short-term survival periods.
  • CONCLUSIONS: Long-term neurobehavioral outcome is related to time-dependent medical events in astrocytoma survivors.
  • The data confirm earlier reports of poorer outcome after medulloblastoma and add new information about clinical markers of poor neurobehavioral outcome in survivors of childhood astrocytoma.
  • [MeSH-major] Astrocytoma / complications. Cerebellar Neoplasms / complications. Cognition Disorders / epidemiology. Medulloblastoma / complications. Mental Disorders / epidemiology. Survivors / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581121.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


43. McCarthy BJ, Propp JM, Davis FG, Burger PC: Time trends in oligodendroglial and astrocytic tumor incidence. Neuroepidemiology; 2008;30(1):34-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time trends in oligodendroglial and astrocytic tumor incidence.
  • BACKGROUND: We hypothesized that the incidences of oligodendrogliomas, anaplastic oligodendrogliomas, and mixed gliomas have significantly increased from the early 1990 s forward, while the incidences of anaplastic and grade II astrocytic tumors have significantly decreased.
  • METHODS: Data for the years 1973-2004 from the Surveillance, Epidemiology and End Results (SEER) public-use data and for 1985-2004 from six collaborating registries of the Central Brain Tumor Registry of the US (CBTRUS) were obtained.
  • RESULTS: Using CBTRUS data, the incidences (per 100,000 person-years) of oligodendrogliomas (APC = 4.7), mixed gliomas (APC = 3.9) and anaplastic oligodendrogliomas (APC = 12.5) have all increased over time, while the incidences of astrocytoma not otherwise specified (APC = -8.1) and fibrillary astrocytoma (APC = -2.1) have decreased.
  • CONCLUSIONS: This study has demonstrated that increases in oligodendroglial tumor incidence correspond to decreases in astrocytic tumor incidence over the same time period.
  • [MeSH-major] Astrocytoma / epidemiology. Brain Neoplasms / epidemiology. Glioma / epidemiology. Oligodendroglioma / epidemiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18259099.001).
  • [ISSN] 1423-0208
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


44. Vladimirova V, Denkhaus D, Soerensen N, Wagner S, Wolff JE, Pietsch T: Low level of microsatellite instability in paediatric malignant astrocytomas. Neuropathol Appl Neurobiol; 2008 Oct;34(5):547-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low level of microsatellite instability in paediatric malignant astrocytomas.
  • The aim of the current study was to determine whether MSI is involved in the pathogenesis of paediatric malignant astrocytomas.
  • METHODS: We screened a cohort of 126 high-grade astrocytoma samples for MSI using a sensitive and precise method of DNA analysis including a panel of five mononucleotide repeats, in combination with immunohistochemistry for DNA mismatch repair (MMR) proteins.
  • RESULTS: We identified low level of MSI (MSI-L) in four of 126 (3.2%) paediatric malignant astrocytic tumours.
  • In MSI-L paediatric malignant astrocytic tumours we detected retained nuclear expression of hMSH6 protein and strong nuclear accumulation of p53 protein indicating possible mutations of TP53.
  • However, this represents only a small subgroup of paediatric gliomas with possible distinct biological features, and the deficiencies of DNA MMR genes do not play a main role in the tumourigenesis of the majority of paediatric malignant astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Microsatellite Instability
  • [MeSH-minor] Child. DNA Mutational Analysis. DNA-Binding Proteins / genetics. Genes, ras / genetics. Humans. Immunohistochemistry. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053027.001).
  • [ISSN] 1365-2990
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


45. González-Agüero G, Gutiérrez AA, González-Espinosa D, Solano JD, Morales R, González-Arenas A, Cabrera-Muñoz E, Camacho-Arroyo I: Progesterone effects on cell growth of U373 and D54 human astrocytoma cell lines. Endocrine; 2007 Oct;32(2):129-35
Hazardous Substances Data Bank. MIFEPRISTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone effects on cell growth of U373 and D54 human astrocytoma cell lines.
  • Astrocytomas are the most frequent primary brain tumors and constitute a leading cause of cancer-related deaths.
  • We studied the effects of progesterone and its antagonist, RU486, on cell growth of two human astrocytoma cell lines with different evolution grade (U373, grade III; and D54, grade IV).
  • RU486 (10 muM) blocked progesterone effects in both astrocytoma cell lines.
  • DNA fragmentation (TUNEL) assay showed that the diminution in the number of astrocytoma cells produced by RU486 was not by apoptosis.
  • Our data suggest that progesterone induces cell growth of human astrocytoma cell lines through the interaction with its nuclear receptor.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Proliferation / drug effects. Progesterone / pharmacology. Progestins / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Hormone Antagonists / pharmacology. Humans. Mifepristone / pharmacology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18008187.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormone Antagonists; 0 / Progestins; 320T6RNW1F / Mifepristone; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


46. Assimakopoulou M, Kondyli M, Gatzounis G, Maraziotis T, Varakis J: Neurotrophin receptors expression and JNK pathway activation in human astrocytomas. BMC Cancer; 2007;7:202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurotrophin receptors expression and JNK pathway activation in human astrocytomas.
  • The aim of this exploratory study was to investigate the expression levels of neurotrophin receptors, Trks and p75NTR, and the activation of JNK pathway in human astrocytomas and in adjacent non-neoplastic brain tissue.
  • METHODS: Formalin-fixed paraffin-embedded serial sections from 33 supratentorial astrocytomas (5 diffuse fibrillary astrocytomas, WHO grade II; 6 anaplastic astrocytomas, WHO grade III; 22 glioblastomas multiforme, WHO grade IV) were immunostained following microwave pretreatment.
  • The labeling index (LI), defined as the percentage of positive (labeled) cells out of the total number of tumor cells counted, was determined.
  • RESULTS: Moderate to strong, granular cytoplasmic immunoreactivity for TrkA, TrkB and TrkC receptors was detected in greater than or equal to 10% of tumor cells in the majority of tumors independently of grade; on the contrary, p75NTR receptor expression was found in a small percentage of tumor cells (approximately 1%) in some tumors.
  • The endothelium of tumor capillaries showed conspicuous immunoreactivity for TrkB receptor.
  • Phosphorylated forms of JNK (pJNK) and c-Jun (pc-Jun) were significantly co-expressed in a tumor grade-dependent manner (p < 0.05).
  • CONCLUSION: In the context of astrocytomas, Trk receptors (TrkA, TrkB, TrkC) expression may promote tumor growth independently of grade.
  • Considering the fact that regional tumor heterogeneity may be a limiting factor for immunohistochemical studies, the significance of the reverse relationship between Trk receptors and pc-Jun/pJNK LIs with respect to biological behavior of human astrocytomas requires further evaluation.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. MAP Kinase Kinase 4 / metabolism. Nerve Tissue Proteins / biosynthesis. Nerve Tissue Proteins / genetics. Receptors, Nerve Growth Factor / biosynthesis. Receptors, Nerve Growth Factor / genetics
  • [MeSH-minor] Apoptosis. Cell Line, Tumor. Cytoplasm / metabolism. Humans. Phosphorylation. Receptor, trkA / metabolism. Receptor, trkB / metabolism. Receptor, trkC / metabolism. bcl-2-Associated X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1027-35 [10694553.001]
  • [Cites] Mol Cell Neurosci. 2007 Feb;34(2):271-9 [17188890.001]
  • [Cites] Curr Opin Neurobiol. 2000 Jun;10(3):381-91 [10851172.001]
  • [Cites] Cell. 2000 Oct 13;103(2):239-52 [11057897.001]
  • [Cites] Curr Opin Neurobiol. 2001 Jun;11(3):272-80 [11399424.001]
  • [Cites] Cancer Lett. 2001 Aug 28;169(2):107-14 [11431098.001]
  • [Cites] Curr Opin Pharmacol. 2001 Aug;1(4):398-403 [11710739.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):250-5 [12517805.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):203-16 [12612655.001]
  • [Cites] J Biosci. 2003 Mar;28(2):181-8 [12711810.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14421-6 [14614136.001]
  • [Cites] Nat Rev Neurosci. 2003 Apr;4(4):299-309 [12671646.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):430-46 [15136790.001]
  • [Cites] Childs Nerv Syst. 2004 Jun;20(6):412-9 [15138791.001]
  • [Cites] Brain Res. 2004 Aug 13;1017(1-2):53-60 [15261099.001]
  • [Cites] Neurochem Int. 1997 Apr-May;30(4-5):347-74 [9106250.001]
  • [Cites] J Neurosci. 1997 Jan 15;17(2):530-42 [8987776.001]
  • [Cites] Acta Neuropathol. 1998 Apr;95(4):325-32 [9560008.001]
  • [Cites] Acta Neuropathol. 1998 Oct;96(4):357-64 [9797000.001]
  • [Cites] Eur J Neurosci. 2005 Jan;21(2):363-77 [15673436.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):137-60 [15674475.001]
  • [Cites] J Neurosci. 2005 Jun 1;25(22):5455-63 [15930396.001]
  • [Cites] Anat Sci Int. 2005 Dec;80(4):223-8 [16333918.001]
  • [Cites] Curr Alzheimer Res. 2006 Feb;3(1):19-24 [16472198.001]
  • [Cites] J Neurosci. 2006 Jul 19;26(29):7756-66 [16855103.001]
  • [Cites] J Neurooncol. 1999;45(1):1-8 [10728904.001]
  • (PMID = 17971243.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NGFR protein, human; 0 / Nerve Tissue Proteins; 0 / Receptors, Nerve Growth Factor; 0 / bcl-2-Associated X Protein; EC 2.7.10.1 / Receptor, trkA; EC 2.7.10.1 / Receptor, trkB; EC 2.7.10.1 / Receptor, trkC; EC 2.7.12.2 / MAP Kinase Kinase 4
  • [Other-IDs] NLM/ PMC2180182
  •  go-up   go-down


47. Chen L, Wang Y, Zhu XZ: [Pilomyxoid astrocytoma: a clinicopathologic study of three cases]. Zhonghua Bing Li Xue Za Zhi; 2006 Dec;35(12):727-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pilomyxoid astrocytoma: a clinicopathologic study of three cases].
  • OBJECTIVE: To study the clinicopathologic features of pilomyxoid astrocytoma (PmA).
  • Histologically, the tumor was composed of bipolar spindle cells setting in a strikingly mucinous background.
  • There was a marked proliferation of vessels within the tumor.
  • In some areas, the tumor cells exhibited an angiocentric growth pattern.
  • The biphasic pattern noted in a classic pilocytic astrocytoma was not found in PmA.
  • Immunohistochemcal study showed that the tumor cells were diffusely positive for GFAP.
  • CONCLUSIONS: PmA is a distinctive variant of pilocytic astrocytoma with subtle histologic differences.
  • Compared with conventional pilocytic astrocytoma, PmA behaves more aggressively.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology. Optic Nerve Glioma / pathology. Third Ventricle / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374256.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen
  •  go-up   go-down


48. Birlik B, Canda S, Ozer E: Tumour vascularity is of prognostic significance in adult, but not paediatric astrocytomas. Neuropathol Appl Neurobiol; 2006 Oct;32(5):532-8
MedlinePlus Health Information. consumer health - Seniors' Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour vascularity is of prognostic significance in adult, but not paediatric astrocytomas.
  • Astrocytomas are the commonest type of brain tumours in adults and children.
  • Due to the evidence that vascular changes are important histological features of astrocytomas, the aim of this study was to investigate prognostic significance of tumour vascularity in paediatric and adult astrocytomas.
  • Study population consisted of 70 patients (45 adult and 25 children) with histologically proven diagnosis of astrocytoma with no history of previous therapy.
  • Histological classification and grading were also assessed using the World Health Organization system.
  • In contrast to the results in paediatric astrocytomas, tumour vascularity in adult tumours correlated significantly with postoperative survival by univariate analysis (P < 0.05).
  • We conclude that histological quantification of tumour vascularity is a significant prognosticator in adult astrocytomas, but not in children.
  • Our data do not support the validity of applications of antiangiogenic agents in paediatric astrocytic tumours, particularly pilocytic astrocytomas.
  • [MeSH-major] Aging / pathology. Astrocytoma / blood supply. Astrocytoma / pathology. Brain Neoplasms / blood supply. Brain Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16972887.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antigens, CD31
  •  go-up   go-down


49. Banerjee HN, Zhang L: Deciphering the finger prints of brain cancer astrocytoma in comparison to astrocytes by using near infrared Raman spectroscopy. Mol Cell Biochem; 2007 Jan;295(1-2):237-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deciphering the finger prints of brain cancer astrocytoma in comparison to astrocytes by using near infrared Raman spectroscopy.
  • To explore the biochemical differences between brain cancer cells Astrocytoma and normal cells Astrocyte, we investigated the Raman spectra of single cell from these two cell types and analyzed the difference in spectra and intensity.
  • The Raman spectra of brain cancer Astrocytoma shows that the structural changes of cancer cells happen so that many biological functions of these cells are lost.
  • [MeSH-major] Astrocytes / chemistry. Astrocytoma / chemistry. Brain Neoplasms / chemistry. Spectroscopy, Near-Infrared. Spectrum Analysis, Raman

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16924417.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / G11HD 34280-05
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


50. Berg AL, Olson TJ, Feldstein NA: Cerebellar pilocytic astrocytoma with auditory presentation: case study. J Child Neurol; 2005 Nov;20(11):914-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellar pilocytic astrocytoma with auditory presentation: case study.
  • The results were suggestive of a space-occupying lesion, and the patient was referred to a pediatric neurologist and neurosurgeon.
  • A cerebellar pilocytic astrocytoma was found.
  • [MeSH-major] Astrocytoma / complications. Cerebellar Neoplasms / complications. Hearing Loss / etiology

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16417863.001).
  • [ISSN] 0883-0738
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Shah B, Lipper MH, Laws ER, Lopes MB, Spellman MJ Jr: Posterior pituitary astrocytoma: a rare tumor of the neurohypophysis: a case report. AJNR Am J Neuroradiol; 2005 Aug;26(7):1858-61
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posterior pituitary astrocytoma: a rare tumor of the neurohypophysis: a case report.
  • Astrocytoma, or pituicytoma, of the posterior pituitary is a relatively rare entity consisting of poorly characterized glial tumor cells.
  • We report two cases of posterior pituitary astrocytomas in middle-aged women presenting as focal lesions of the neurohypophysis.
  • A review of the literature reveals only a few reports of this tumor, and there has been scanty discussion of the imaging findings of posterior pituitary astrocytomas compared with lesions of the anterior pituitary gland.
  • [MeSH-major] Astrocytoma / diagnosis. Magnetic Resonance Imaging. Pituitary Gland, Posterior / pathology. Pituitary Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091544.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 6
  •  go-up   go-down


52. Matsuoka H, Maruyama D, Takegami T, Hamasaki T, Kakita K, Mineura K: [A case of pontine astrocytoma with unusual neuroimaging features]. No Shinkei Geka; 2009 Oct;37(10):1001-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pontine astrocytoma with unusual neuroimaging features].
  • We would like to report a rare case of pontine glioma with unusual neuroimaging features.
  • Fever of unknown origin continued for a month after the VP shunt.
  • Magnetic resonance imaging (MRI) revealed hydrocephalus and pontine swelling, and serial MRI suggested brainstem tumor extending to the bilateral thalamus.
  • The patient underwent stereotactic biopsy of the left thalamic tumor, under general anesthesia, and the histological diagnosis was anaplastic astrocytoma.
  • Diffuse pontine glioma rarely increases without cranial nerve deficits.
  • In the present case, pontine glioma extended to the bilateral thalamus symmetrically.
  • It was difficult to diagnose the presented lesion as pontine glioma in the early period because of its unusual neuroimaging.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Stem Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19882961.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


53. Ibeas E, Fuentes L, Martín R, Hernández M, Nieto ML: Inflammatory protein sPLA(2)-IIA abrogates TNFalpha-induced apoptosis in human astroglioma cells: Crucial role of ERK. Biochim Biophys Acta; 2009 Dec;1793(12):1837-47

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory protein sPLA(2)-IIA abrogates TNFalpha-induced apoptosis in human astroglioma cells: Crucial role of ERK.
  • Brain injury induces the expression of well-known cytokines, such as tumor necrosis factor-alpha (TNFalpha), and other, which functions are less understood, as secreted phospholipase A(2) group IIA (sPLA(2)-IIA).
  • Since in pathological processes, cytokines function coordinately in networks, to further explore the actions of sPLA(2)-IIA in tumorigenesis, we investigated the effect of sPLA(2)-IIA in the presence of TNFalpha in human 1321N1 astrocytoma cells.
  • These findings thus indicate that sPLA(2)-IIA and TNFalpha transduction pathways interact to modulate inflammatory responses and provide additional insights about the capacity of sPLA(2)-IIA to promote apoptosis resistance in astrocytoma cells.
  • [MeSH-major] Apoptosis. Astrocytoma / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Group II Phospholipases A2 / metabolism. Inflammation Mediators / metabolism. MAP Kinase Signaling System. Tumor Necrosis Factor-alpha / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cyclooxygenase 2 / biosynthesis. Cyclooxygenase 2 / genetics. Enzyme Induction / drug effects. Enzyme Induction / genetics. Humans. Inflammation / genetics. Inflammation / metabolism. Phosphorylation / drug effects. Phosphorylation / genetics. Protein Structure, Tertiary / genetics. Receptors, Tumor Necrosis Factor, Type I / genetics. Receptors, Tumor Necrosis Factor, Type I / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19850087.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Inflammation Mediators; 0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Tumor Necrosis Factor-alpha; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.1.1.4 / Group II Phospholipases A2
  •  go-up   go-down


54. Choi K, Choi C: Proapoptotic ginsenosides compound K and Rh enhance Fas-induced cell death of human astrocytoma cells through distinct apoptotic signaling pathways. Cancer Res Treat; 2009 Mar;41(1):36-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proapoptotic ginsenosides compound K and Rh enhance Fas-induced cell death of human astrocytoma cells through distinct apoptotic signaling pathways.
  • PURPOSE: Malignant astrocytomas are among the commonest primary brain tumors and they have a grave prognosis, and so there is an urgent need to develop effective treatment.
  • In this study, we investigated the molecular mechanisms that are responsible for the anti-tumor effect of ginsenosides on human astrocytoma cells.
  • MATERIALS AND METHODS: We tested 13 different ginsenosides for their anti-tumor effect on human malignant astrocytoma cells in conjunction with Fas stimulation.
  • RESULTS: Among the 13 different ginsenoside metabolites, compound K and Rh(2) induced apoptotic cell death of the astrocytoma cells in a caspase- and p38 MAPK-dependent manner, yet the same treatment had no cytotoxic effect on the primary cultured human astrocytes.
  • CONCLUSION: These results suggest that ginsenoside metabolites in combination with Fas ligand may provide a new strategy to treat malignant astrocytomas, which are tumors that are quite resistant to conventional anti-cancer treatment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Sci. 2006 Jun;91(2):356-64 [16547074.001]
  • [Cites] Planta Med. 2006 Jun;72(7):627-33 [16673329.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1675-87 [9501089.001]
  • [Cites] J Immunol. 1999 Feb 15;162(4):1889-95 [9973455.001]
  • [Cites] EMBO J. 1996 Jan 15;15(2):216-25 [8617197.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1449-56 [7533326.001]
  • [Cites] Biochem Int. 1992 Jul;27(3):501-10 [1417886.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):167-76 [15072464.001]
  • [Cites] Cancer Lett. 2004 Mar 8;205(1):23-9 [15036657.001]
  • [Cites] Brain Res Brain Res Rev. 2004 Jan;44(1):65-81 [14739003.001]
  • [Cites] Mol Carcinog. 2004 Jan;39(1):1-9 [14694442.001]
  • [Cites] Free Radic Biol Med. 2003 Sep 15;35(6):648-61 [12957657.001]
  • [Cites] Blood. 2003 Jul 1;102(1):336-43 [12623840.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):21446-52 [11934900.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(3):724-36 [11784850.001]
  • [Cites] J Korean Med Sci. 2001 Dec;16 Suppl:S38-41 [11748375.001]
  • [Cites] Cancer Lett. 2007 Nov 8;257(1):79-86 [17692455.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):1909-19 [17620423.001]
  • [Cites] Neurosci Lett. 2007 Jun 21;421(1):37-41 [17548155.001]
  • [Cites] Cell Biol Int. 2007 Sep;31(9):1027-35 [17468017.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3100-12 [17496909.001]
  • [Cites] Brain Res. 2007 Mar 9;1136(1):190-9 [17239831.001]
  • [Cites] Science. 2006 Jun 30;312(5782):1882-3 [16809515.001]
  • [Cites] Liver Int. 2005 Oct;25(5):1069-73 [16162168.001]
  • (PMID = 19688070.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2699093
  • [Keywords] NOTNLM ; Apoptosis / Astrocytoma / Fas / Ginsenoside / Reactive oxygen species
  •  go-up   go-down


55. Shipman TL: Acute v pattern esotropia without abduction deficit, secondary to a posterior fossa pilocytic astrocytoma. J Pediatr Ophthalmol Strabismus; 2009 Jul-Aug;46(4):235-7
Genetic Alliance. consumer health - Pilocytic astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute v pattern esotropia without abduction deficit, secondary to a posterior fossa pilocytic astrocytoma.
  • A case of acute esotropia with bilateral inferior oblique muscle overaction in a 4-year-old boy with a posterior fossa pilocytic astrocytoma is reported.
  • After tumor excision, the esotropia and oblique dysfunction resolved.
  • [MeSH-major] Astrocytoma / complications. Cranial Fossa, Posterior. Esotropia / etiology. Eye Movements / physiology. Infratentorial Neoplasms / complications. Oculomotor Muscles / physiopathology

  • Genetic Alliance. consumer health - Esotropia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009, SLACK Incorporated.
  • (PMID = 19645405.001).
  • [ISSN] 0191-3913
  • [Journal-full-title] Journal of pediatric ophthalmology and strabismus
  • [ISO-abbreviation] J Pediatr Ophthalmol Strabismus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Jones DT, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K, Collins VP: Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res; 2008 Nov 01;68(21):8673-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.
  • Brain tumors are the most common solid tumors of childhood, and pilocytic astrocytomas (PA) are the most common central nervous system tumor in 5 to 19 year olds.
  • This rearrangement, which was not observed in a series of 244 higher-grade astrocytomas, results in an in-frame fusion gene incorporating the kinase domain of the BRAF oncogene.
  • This is the first report of BRAF activation through rearrangement as a frequent feature in a sporadic tumor.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Gene Duplication. Gene Fusion. Proto-Oncogene Proteins B-raf / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Res. 2002 Mar;12(3):458-61 [11875034.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4745-51 [18408760.001]
  • [Cites] Childs Nerv Syst. 1997 Jan;13(1):17-23 [9083697.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):239-43 [9107428.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jul 15;104(2):157-60 [9666811.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):94-101 [15630448.001]
  • [Cites] J Biol Chem. 2005 Apr 22;280(16):16244-53 [15710605.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Neurology. 2005 Oct 25;65(8):1335-6 [16247081.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]
  • [Cites] J Invest Dermatol. 2007 Jun;127(6):1468-70 [17301836.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4609-16 [17297459.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Neuropediatrics. 2007 Apr;38(2):61-3 [17712732.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] Oncogene. 2008 May 15;27(22):3122-33 [18071315.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):722-9 [18438408.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • (PMID = 18974108.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / CRUK/ A6618; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Other-IDs] NLM/ PMC2577184; NLM/ UKMS2350
  •  go-up   go-down


57. Zeng Y, Yang Z, Long XD, You C: Inhibition of all-trans retinoic acid on MDM2 gene expression in astrocytoma cell line SHG-44. Neurosci Bull; 2008 Oct;24(5):297-304
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of all-trans retinoic acid on MDM2 gene expression in astrocytoma cell line SHG-44.
  • OBJECTIVE: To investigate the impact of all-trans retinoic acid (ATRA) on MDM2 gene expression in astrocytoma cell line SHG-44, and to provide basic data for further research on the progression mechanism and gene therapy of human astrocytoma.
  • The expressions of MDM2 protein in WHO grade II and grade IV astrocytomas were determined by immunohistochemical streptavidin-peroxidase method.
  • Moreover, the percentages of MDM2-positive protein were 24.00% (6/25) and 56.52% (13/23) (chi(2) = 5.298, P = 0.021) in WHO grade II and grade IV astrocytomas, respectively, suggesting that the expression of MDM2 protein may increase along with the elevation of astrocytoma malignancy.
  • CONCLUSION: ATRA can inhibit MDM2 gene expression in SHG-44 cells, and MDM2 is related to astrocytoma progression.
  • [MeSH-minor] Astrocytoma / metabolism. Astrocytoma / pathology. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Size / drug effects. Humans. Oligonucleotide Array Sequence Analysis / methods. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):731-6 [15644444.001]
  • [Cites] Ai Zheng. 2006 Dec;25(12):1470-6 [17166369.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):15-29 [10721693.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2358-65 [16985070.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):419-30 [10690732.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5481-4 [15994915.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8200-8 [16166295.001]
  • [Cites] FEBS Lett. 2005 Jul 18;579(18):3965-9 [15996664.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):192-8 [16354690.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1984 Jul;6(4):241-3 [6525937.001]
  • [Cites] Brain Res Mol Brain Res. 2001 Feb 19;87(1):100-8 [11223164.001]
  • [Cites] Mol Cancer Res. 2003 Dec;1(14 ):993-1000 [14707282.001]
  • (PMID = 18839023.001).
  • [ISSN] 1673-7067
  • [Journal-full-title] Neuroscience bulletin
  • [ISO-abbreviation] Neurosci Bull
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin; EC 2.3.2.27 / MDM2 protein, human; EC 2.3.2.27 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


58. Isaac AO, Kawikova I, Bothwell AL, Daniels CK, Lai JC: Manganese treatment modulates the expression of peroxisome proliferator-activated receptors in astrocytoma and neuroblastoma cells. Neurochem Res; 2006 Nov;31(11):1305-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Manganese treatment modulates the expression of peroxisome proliferator-activated receptors in astrocytoma and neuroblastoma cells.
  • We investigated the effects of manganese chloride treatment (0.01-4 mM) on protein expression of PPAR isoforms (alpha, beta, and gamma) in human astrocytoma (U87) and neuroblastoma (SK-N-SH) cells.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Manganese Poisoning / metabolism. Neuroblastoma / metabolism. Peroxisome Proliferator-Activated Receptors / biosynthesis
  • [MeSH-minor] Cell Line, Tumor. Cell Nucleus / drug effects. Cell Nucleus / metabolism. Cytosol / drug effects. Cytosol / metabolism. Humans. Immunoblotting. Nuclear Proteins / biosynthesis. Nuclear Proteins / genetics. PPAR alpha / metabolism. PPAR gamma / metabolism. PPAR-beta / metabolism. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17053972.001).
  • [ISSN] 0364-3190
  • [Journal-full-title] Neurochemical research
  • [ISO-abbreviation] Neurochem. Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20RR016454
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / PPAR alpha; 0 / PPAR gamma; 0 / PPAR-beta; 0 / Peroxisome Proliferator-Activated Receptors
  •  go-up   go-down


59. Ceruti S, Mazzola A, Abbracchio MP: Proteasome inhibitors potentiate etoposide-induced cell death in human astrocytoma cells bearing a mutated p53 isoform. J Pharmacol Exp Ther; 2006 Dec;319(3):1424-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteasome inhibitors potentiate etoposide-induced cell death in human astrocytoma cells bearing a mutated p53 isoform.
  • Here we show that human astrocytoma ADF cells (which are resistant to "mitochondriotropic" agents as well as to the antineoplastic drug etoposide and to proteasome inhibitors when used alone) undergo dramatic apoptotic death when exposed to a combination protocol based on the use of etoposide in the presence of proteasome inhibitors.
  • We also show that sensitization of cells to the combination protocol involved the nuclear relocalization of p53, despite the presence of a polymorphism in its DNA-binding domain, suggesting the likely induction of p53-dependent proapoptotic genes.
  • In conclusion, use of etoposide in combination with proteasome inhibitors may represent an effective strategy to restore sensitivity to apoptosis in human astrocytoma cells bearing multiple defects of intracellular apoptotic pathways.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Etoposide / pharmacology. Genes, p53 / genetics. Proteasome Endopeptidase Complex / drug effects
  • [MeSH-minor] Amino Acid Sequence. Apoptosis / drug effects. Blotting, Western. Caspases / metabolism. Cell Death / drug effects. Cell Line, Tumor. Cloning, Molecular. Drug Resistance, Neoplasm / drug effects. Humans. Membrane Potentials / drug effects. Mitochondria / drug effects. Mitochondria / metabolism. Molecular Sequence Data. Mutation / genetics. Phosphorylation. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / isolation & purification. Signal Transduction / drug effects. Subcellular Fractions / drug effects. Subcellular Fractions / enzymology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16971507.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / RNA, Neoplasm; 6PLQ3CP4P3 / Etoposide; EC 3.4.22.- / Caspases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


60. Strazzer S, Zucca C, Fiocchi I, Genitori L, Castelli E: Epilepsy and neuropsychologic deficit in a child with cerebellar astrocytoma. J Child Neurol; 2006 Sep;21(9):817-20
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epilepsy and neuropsychologic deficit in a child with cerebellar astrocytoma.
  • We report the case of a 32-month-old female patient presenting with cerebellar pilocytic astrocytoma with epileptic seizures, psychomotor delay, and severe language delay.
  • Usually, the typical onset of cerebellar tumor is characterized by raised intracranial pressure and cerebellar incoordination.
  • A review of the few cases reported in the literature evidencing epileptic seizures symptomatic of a focal, nondegenerative mass limited to the cerebellum is included.
  • Moreover, a discussion about the cerebellar contribution to nonmotor functions in children is presented, in particular following tumor resection.
  • [MeSH-major] Astrocytoma / complications. Cerebellar Neoplasms / complications. Developmental Disabilities / etiology. Epilepsy / etiology

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Developmental Disabilities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16970895.001).
  • [ISSN] 0883-0738
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


61. McCall T, Rao G, Jensen R: Development and rapid growth of a desmoid tumor in the surgical corridor after suboccipital craniotomy for recurrent low-grade astrocytoma. J Neurooncol; 2006 Nov;80(2):167-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and rapid growth of a desmoid tumor in the surgical corridor after suboccipital craniotomy for recurrent low-grade astrocytoma.
  • We present the rare case of a desmoid tumor that occurred in the surgical corridor after suboccipital craniotomy for recurrent low-grade astrocytoma.
  • A 30-year-old woman underwent a repeat suboccipital craniotomy for recurrent low-grade astrocytoma.
  • The mass was resected en bloc.
  • Histology demonstrated clear surgical margins and a tumor of low cellularity consistent with a desmoid tumor.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / pathology. Fibromatosis, Aggressive / pathology. Postoperative Complications / pathology

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645711.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


62. Olavarria G, Reitman AJ, Goldman S, Tomita T: Post-shunt ascites in infants with optic chiasmal hypothalamic astrocytoma: role of ventricular gallbladder shunt. Childs Nerv Syst; 2005 May;21(5):382-4
MedlinePlus Health Information. consumer health - Hydrocephalus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-shunt ascites in infants with optic chiasmal hypothalamic astrocytoma: role of ventricular gallbladder shunt.
  • INTRODUCTION: We report a series of infants with optic chiasmal hypothalamic astrocytomas (OCHAs) who developed abdominal ascites following ventriculo-peritoneal (VP) shunting.
  • [MeSH-major] Ascites. Astrocytoma / surgery. Hydrocephalus / surgery. Hypothalamic Neoplasms / surgery. Optic Chiasm / surgery. Ventriculoperitoneal Shunt / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15449089.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Momota H, Narita Y, Miyakita Y, Hosono A, Makimoto A, Shibui S: Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. Pediatr Blood Cancer; 2010 Sep;55(3):577-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation.
  • We present a case of a 12-year-old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ).
  • Although alkylating agents such as TMZ are known to induce secondary hematologic malignancy, only several cases of treatment-related acute leukemia have been reported after TMZ-alone chemotherapy for malignant gliomas.
  • We demonstrate a rare case of TMZ-related ALL in a child with glioma possibly associated with a germline TP53 mutation.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Frontal Lobe. Genes, p53 / genetics. Germ-Line Mutation. Neoplasms, Second Primary / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / chemically induced

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • [ErratumIn] Pediatr Blood Cancer. 2011 Mar;56(3):509. Nariata, Yoshitaka [corrected to Narita, Yoshitaka]
  • (PMID = 20658636.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


64. Levidou G, El-Habr E, Saetta AA, Bamias C, Katsouyanni K, Patsouris E, Korkolopoulou P: P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature. J Neurooncol; 2010 Dec;100(3):363-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature.
  • During the past few decades, researchers have been looking for parameters with an impact on the prognosis of patients with astrocytic tumors. p53 is one of the most widely investigated molecules in human gliomas.
  • We aimed to comprehensively review the evidence for the prognostic usefulness of p53 immunohistochemical expression in paraffin-embedded tissue specimens from diffusely infiltrating astrocytomas.
  • We conducted a systematic review of the PubMed database through December 2007 to identify cohort studies that evaluated p53 immunohistochemical expression as a prognostic marker for human astrocytomas.
  • A meta-analysis was performed on the studies that applied Cox models and had adjusted the hazard ratio of p53 expression with tumor grade and patients' age.
  • After almost 20 years of research, published evidence does not substantiate the usefulness of p53 immunohistochemical expression as a prognostic marker in patients with astrocytic neoplasms.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Biomarkers / metabolism. Biomarkers, Tumor / metabolism. Female. Humans. Linear Models. Male. Middle Aged. Predictive Value of Tests. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurooncol. 2010 Dec;100(3):373. Katsougiannis, Klea [corrected to Katsouyanni, Klea]
  • (PMID = 20461443.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


65. Blum AE, Walsh BC, Dubyak GR: Extracellular osmolarity modulates G protein-coupled receptor-dependent ATP release from 1321N1 astrocytoma cells. Am J Physiol Cell Physiol; 2010 Feb;298(2):C386-96
Hazardous Substances Data Bank. PROBENECID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracellular osmolarity modulates G protein-coupled receptor-dependent ATP release from 1321N1 astrocytoma cells.
  • We previously reported that ATP release from 1321N1 human astrocytoma cells could be stimulated either by activation of G protein-coupled receptors (GPCR) or by hypotonic stress.
  • Thus, we provide the new finding that GPCR-regulated ATP release from 1321N1 astrocytoma cells is remarkably sensitive to both positive and negative modulation by extracellular osmolarity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Channels (Austin). 2009 Sep-Oct;3(5):323-36 [19713739.001]
  • [Cites] J Neurochem. 2008 Jun 1;105(6):2260-70 [18315563.001]
  • [Cites] J Physiol. 2007 Oct 15;584(Pt 2):419-35 [17702822.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Dec;23(6):755-61 [11104728.001]
  • [Cites] J Physiol. 2001 May 1;532(Pt 3):759-69 [11313444.001]
  • [Cites] J Gen Physiol. 2001 Sep;118(3):251-66 [11524456.001]
  • [Cites] J Membr Biol. 2002 Jan 15;185(2):93-102 [11891568.001]
  • [Cites] J Gen Physiol. 2002 Jun;119(6):511-20 [12034759.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Aug;283(2):C569-78 [12107067.001]
  • [Cites] J Neurochem. 2003 Jan;84(1):3-9 [12485396.001]
  • [Cites] Acta Physiol Scand. 2003 Feb;177(2):119-47 [12558550.001]
  • [Cites] J Neurophysiol. 2003 Apr;89(4):1870-7 [12686569.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23331-42 [12684505.001]
  • [Cites] Mol Pharmacol. 2003 Oct;64(4):785-95 [14500734.001]
  • [Cites] Neurochem Res. 2004 Jan;29(1):239-46 [14992283.001]
  • [Cites] FEBS Lett. 2004 Aug 13;572(1-3):65-8 [15304325.001]
  • [Cites] J Physiol. 2004 Sep 15;559(Pt 3):799-812 [15272030.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Nov;287(5):C1389-95 [15475518.001]
  • [Cites] J Biol Chem. 1985 Mar 25;260(6):3440-50 [3838314.001]
  • [Cites] Am J Physiol. 1992 Aug;263(2 Pt 1):C348-56 [1514583.001]
  • [Cites] J Neurochem. 1993 Oct;61(4):1506-14 [8397296.001]
  • [Cites] J Gen Physiol. 1994 May;103(5):787-805 [7913485.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):13067 [7809171.001]
  • [Cites] Am J Physiol. 1996 Mar;270(3 Pt 1):C711-30 [8638650.001]
  • [Cites] Am J Physiol. 1996 Jun;270(6 Pt 1):C1703-8 [8764153.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):12020-5 [8876255.001]
  • [Cites] Mol Biol Cell. 1996 Nov;7(11):1679-90 [8930892.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15735-40 [9861039.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 16;103(20):7655-9 [16682648.001]
  • [Cites] Pflugers Arch. 2006 Jul;452(4):396-406 [16604368.001]
  • [Cites] IUBMB Life. 2006 Jul;58(7):409-19 [16801216.001]
  • [Cites] J Physiol. 2006 May 1;572(Pt 3):677-89 [16527858.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22992-3002 [16754672.001]
  • [Cites] Nat Med. 2006 Aug;12(8):950-4 [16862155.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Oct;291(4):C757-71 [16687471.001]
  • [Cites] Glia. 2006 Nov 15;54(7):758-73 [17006904.001]
  • [Cites] EMBO J. 2006 Nov 1;25(21):5071-82 [17036048.001]
  • [Cites] EMBO J. 2007 Feb 7;26(3):657-67 [17235286.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Mar;320(3):1068-77 [17148779.001]
  • [Cites] Mol Cells. 2007 Feb 28;23(1):11-6 [17464206.001]
  • [Cites] Glia. 2007 Jul;55(9):917-25 [17437307.001]
  • [Cites] Cell Mol Life Sci. 2007 Jun;64(12):1471-83 [17375261.001]
  • [Cites] J Neurosci. 2008 Jan 16;28(3):681-95 [18199768.001]
  • [Cites] J Neurosci. 2008 Feb 20;28(8):1804-15 [18287497.001]
  • [Cites] J Cell Physiol. 2008 Jul;216(1):14-28 [18300263.001]
  • [Cites] Cell Res. 2008 May;18(5):558-65 [18414449.001]
  • [Cites] J Neurosci. 2008 Apr 30;28(18):4702-11 [18448647.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Jul;295(1):C231-41 [18495810.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Sep;295(3):C761-7 [18596212.001]
  • [Cites] Pharmacology. 2008;82(4):257-63 [18841035.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Dec;295(6):C1550-60 [18923056.001]
  • [Cites] Glia. 2009 Feb;57(3):258-69 [18837047.001]
  • [Cites] Physiol Rev. 2009 Jan;89(1):193-277 [19126758.001]
  • [Cites] J Pharmacol Exp Ther. 2009 Feb;328(2):409-18 [19023039.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Feb 27;380(1):50-3 [19150332.001]
  • [Cites] J Physiol Sci. 2009 Jan;59(1):3-21 [19340557.001]
  • [Cites] J Physiol. 2009 May 15;587(Pt 10):2141-9 [19171657.001]
  • [Cites] J Physiol. 2009 May 15;587(Pt 10):2197-209 [19188250.001]
  • [Cites] J Neurosci. 2009 May 27;29(21):7092-7 [19474335.001]
  • [Cites] Annu Rev Biomed Eng. 2009;11:135-62 [19400711.001]
  • [Cites] J Biol Chem. 2009 Jul 31;284(31):20638-48 [19439413.001]
  • [Cites] Neuropharmacology. 2009 Sep;57(4):343-6 [19577581.001]
  • [Cites] FEBS J. 2009 Nov;276(21):6258-70 [19780818.001]
  • [Cites] Am J Respir Cell Mol Biol. 2009 Nov;41(5):525-34 [19213873.001]
  • [Cites] Br J Pharmacol. 1999 Sep;128(1):35-40 [10498832.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Dec;311(3):1097-104 [15292461.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Jan;288(1):C204-13 [15371260.001]
  • [Cites] J Neurochem. 2005 Mar;92(5):1033-43 [15715654.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Nov;315(2):755-63 [16051696.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16466-71 [16254051.001]
  • [Cites] FEBS Lett. 2006 Jan 9;580(1):239-44 [16364313.001]
  • [Cites] Science. 2006 May 12;312(5775):924-7 [16690868.001]
  • (PMID = 19907018.001).
  • [ISSN] 1522-1563
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM036387; United States / NIGMS NIH HHS / GM / R01-GM36387; United States / NHLBI NIH HHS / HL / T32-HL07653; United States / NIGMS NIH HHS / GM / T32-GM07250; United States / NIGMS NIH HHS / GM / T32 GM007250
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anions; 0 / Chelating Agents; 0 / Hypertonic Solutions; 0 / Hypotonic Solutions; 0 / Ion Channels; 0 / Receptor, PAR-1; 0 / Tetanus Toxin; 139890-68-9 / 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester; 1F7A44V6OU / Colforsin; 526U7A2651 / Egtazic Acid; 64657-18-7 / 1,9-dideoxyforskolin; 8L70Q75FXE / Adenosine Triphosphate; EC 3.4.21.5 / Thrombin; EC 3.6.5.2 / rho GTP-Binding Proteins; MM6384NG73 / Carbenoxolone; PO572Z7917 / Probenecid
  • [Other-IDs] NLM/ PMC2822496
  •  go-up   go-down


66. Guan X, Lai S, Lackey J, Shi J, Techavipoo U, Moulding HD, Flanders AE, Andrews DW: Revisiting anaplastic astrocytomas II: further characterization of an expansive growth pattern with visually enhanced diffusion tensor imaging. J Magn Reson Imaging; 2008 Dec;28(6):1322-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting anaplastic astrocytomas II: further characterization of an expansive growth pattern with visually enhanced diffusion tensor imaging.
  • PURPOSE: To seek to distinguish and visualize the different magnetic resonance imaging (MRI) growth patterns among malignant gliomas utilizing visually enhanced diffusion tensor imaging (DTI).
  • MATERIALS AND METHODS: Nineteen consecutive patients undergoing image-guided resection of a newly diagnosed malignant glioma underwent add-on acquisition of DTI data based on an Institutional Review Board (IRB)-approved imaging protocol during preoperative MRI scans for routine intraoperative image guidance.
  • Tumor growth patterns were assigned to expansive or mixed/infiltrative classes as described in the companion article (24).
  • Infiltrating tumors were WHO Grade IV astrocytomas and all expansive tumors were either WHO Grade III astrocytomas or WHO Grade II astrocytomas.
  • DTI-based white matter tractography was conducted and the DTI data were fused with anatomical images using an in-house software package we developed to enhance the visualization of the tumor/fiber interface.
  • RESULTS: Out of the 19 tumor patients studied, 11 had infiltrative tumors and the other 8 had expansive tumors.
  • While less clear with 2D axial diffusion color maps, visually enhanced 3D reconstructions of the tumor/fiber interface successfully corroborated distinctive growth patterns.
  • This was particularly evident when viewed in 3D video loops of each tumor/fiber interface.
  • CONCLUSION: We have successfully developed software that visually enhances the anatomic details of the tumor/fiber interface in patients with anaplastic astrocytomas.
  • These data support the existence of a subgroup of patients within the WHO Grade III classification with expansive tumors and a significantly better prognosis.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods. Image Enhancement / methods. Image Processing, Computer-Assisted
  • [MeSH-minor] Adult. Aged. Female. Humans. Imaging, Three-Dimensional. Magnetic Resonance Imaging, Interventional. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19025901.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Holden LJ, Coleman MD: Assessment of the astrogliotic responses of three human astrocytoma cell lines to ethanol, trimethyltin chloride and acrylamide. Toxicology; 2007 Nov 20;241(1-2):75-83
Hazardous Substances Data Bank. ACRYLAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the astrogliotic responses of three human astrocytoma cell lines to ethanol, trimethyltin chloride and acrylamide.
  • The astrogliotic responses of the CCF-STTG1, U251-MG, and U373-MG human astrocytoma lines were determined after exposure to ethanol, trimethyltin chloride (TMTC), and acrylamide over 4, 16, and 24h.
  • Ethanol treatment over 24h, but not at 4 and 16h, resulted in significant increases in GFAP in all three glioma lines at sub-cytotoxic levels; the GFAP responses in the CCF-STTG1 line were the most sensitive, as concentrations of 0.1 and 1mM led to increases in GFAP expression compared with control of 56.8+/-15.7 and 58.9+/-11.5%, respectively (P<0.05).
  • This study underlines the significance of period of exposure, as well as toxin concentration in astrocytoma cellular response to toxic pressure.
  • [MeSH-major] Acrylamide / toxicity. Astrocytoma / pathology. Brain Neoplasms / pathology. Central Nervous System Depressants / toxicity. Ethanol / toxicity. Gliosis / pathology. Trimethyltin Compounds / toxicity
  • [MeSH-minor] Cell Count. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Mitochondria / drug effects. Mitochondria / enzymology. Oxidoreductases / metabolism. Tetrazolium Salts. Thiazoles

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875352.001).
  • [ISSN] 0300-483X
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Central Nervous System Depressants; 0 / Glial Fibrillary Acidic Protein; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Trimethyltin Compounds; 20R035KLCI / Acrylamide; 298-93-1 / thiazolyl blue; 3K9958V90M / Ethanol; EC 1.- / Oxidoreductases
  •  go-up   go-down


68. Aragão Mde F, Otaduy MC, Melo RV, Azevedo Filho HR, Victor EG, Silva JL, Araújo N, Leite Cda C, Valença MM: [Multivoxel spectroscopy with short echo time: choline/N-acetyl-aspartate ratio and the grading of cerebral astrocytomas]. Arq Neuropsiquiatr; 2007 Jun;65(2A):286-94
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivoxel spectroscopy with short echo time: choline/N-acetyl-aspartate ratio and the grading of cerebral astrocytomas].
  • [Transliterated title] Espectroscopia multivoxel com tempo de eco curto: a razão colina/N-acetil-aspartato e a graduação dos astrocitomas cerebrais.
  • The choline/N-acetyl-aspartate (Cho/NAA) ratio, obtained by the multivoxel spectroscopy with short echo time (TE), was evaluated, in the histological grading of the brain astrocytomas (grades I, II and III-IV) in comparison with the normal cerebral parenchyma.
  • A significant increase (p<0.05) in the average ratios of Cho/NAA was observed in the three astrocytoma groups studied in relation to normal tissue, having a tendency to increase with the increase in grading, without any statistic significance, which corresponded to: 0.53+/-0.24 in the control group, 1.19+/-0.49 in grade I, 1.58+/-0.65 in grade II and 5.13+/-8.12 in the high grade group (grades III-IV), with variation in the values encountered.
  • We conclude that multivoxel spectroscopy with short TE can be used in discriminating between normal parenchyma and neoplasm tissue.
  • However, not all neoplasm tissue studied presented an increase in Cho/NAA, especially in the group with higher grade of malignancy.
  • [MeSH-major] Aspartic Acid / metabolism. Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Choline / metabolism. Female. Glioblastoma / pathology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Prospective Studies. Protons. Sensitivity and Specificity. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17607430.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Protons; 30KYC7MIAI / Aspartic Acid; N91BDP6H0X / Choline
  •  go-up   go-down


69. Asano S, Kameyama M, Oura A, Morisato A, Sakai H, Tabuchi Y, Chairoungdua A, Endou H, Kanai Y: L-type amino acid transporter-1 expressed in human astrocytomas, U343MGa. Biol Pharm Bull; 2007 Mar;30(3):415-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L-type amino acid transporter-1 expressed in human astrocytomas, U343MGa.
  • The expression of this transporter is up-regulated in tumor cells and rapidly-growing cells to support their proliferation.
  • Here, we studied the expression of LAT1 and 4F2hc in human cultured cells by real-time PCR and Western blot, and found that human brain astrocytomas, U343MGa, highly expressed LAT1 and 4F2hc mRNAs and proteins.
  • [MeSH-minor] Amino Acids / pharmacology. Antigens, CD98 Heavy Chain / genetics. Antigens, CD98 Heavy Chain / metabolism. Astrocytoma / genetics. Astrocytoma / metabolism. Astrocytoma / pathology. Biological Transport / drug effects. Blotting, Western. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Carbon Radioisotopes. Cell Line. Cell Line, Tumor. Electrophoresis, Polyacrylamide Gel. HT29 Cells. HeLa Cells. Humans. Leucine / metabolism. Leucine / pharmacokinetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation / genetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-Leucine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329830.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Antigens, CD98 Heavy Chain; 0 / Carbon Radioisotopes; 0 / Large Neutral Amino Acid-Transporter 1; 0 / RNA, Messenger; GMW67QNF9C / Leucine
  •  go-up   go-down


70. Hon SF, Wong GK, Zhu XL, Ng HK, Sin NC, Poon WS: Surgical treatment of a neonate with refractory seizures secondary to congenital giant cell astrocytoma: case report and literature review. Hong Kong Med J; 2006 Jun;12(3):222-4
MedlinePlus Health Information. consumer health - Seizures.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of a neonate with refractory seizures secondary to congenital giant cell astrocytoma: case report and literature review.
  • Most congenital brain tumours are neuro-ectodermal tumours and medulloblastomas; giant cell astrocytoma and other tuberous sclerosis-related tumours are rare.
  • Surgical resection was performed successfully and pathology revealed the tumour to be a giant cell astrocytoma.

  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16760552.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anticonvulsants
  • [Number-of-references] 8
  •  go-up   go-down


71. Klein O, Grignon Y, Civit T, Pinelli C, Auque J, Marchal JC: [Childhood diencephalic pilocytic astrocytoma. A review of seven observations]. Neurochirurgie; 2006 Feb;52(1):3-14
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Childhood diencephalic pilocytic astrocytoma. A review of seven observations].
  • [Transliterated title] Les astrocytomes pilocytiques du diencephale de l'enfant. à propos de sept observations.
  • BACKGROUND AND PURPOSE: Pilocytic astrocytoma (PA) is a WHO grade I tumor of the central nervous system mostly arising in children and young adults.
  • Tumor locations were as followed: right thalamus: 2, both thalami: 1, hypothalamus: 3, and right basal ganglia: 1.
  • Three children died, two by tumor progression and one death related to late side-effects of RT.
  • We observed tumor regression in two patients at 1 and 17 years after the beginning of treatment.
  • The tumor can be controlled by a partial surgical removal, and a residual tumor can sometimes decrease in size after surgery.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Hypothalamic Neoplasms / surgery. Thalamic Diseases / surgery

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16609655.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


72. Yoshino A, Katayama Y, Yokoyama T, Watanabe T, Ogino A, Ota T, Komine C, Fukushima T, Kusama K: Therapeutic implications of interferon regulatory factor (IRF)-1 and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to interferon (IFN)-beta in glioblastoma cells and prognostic value for DIA. J Neurooncol; 2005 Sep;74(3):249-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic implications of interferon regulatory factor (IRF)-1 and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to interferon (IFN)-beta in glioblastoma cells and prognostic value for DIA.
  • Furthermore, we attempted to determine whether or not IRF-1 and IRF-2 act as additional prognostic indicators in diffusely infiltrating astrocytomas (DIA).
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Interferon Regulatory Factor-1 / metabolism. Interferon Regulatory Factor-2 / metabolism. Interferon-beta / pharmacology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Apoptosis / physiology. Blotting, Western. Caspases / drug effects. Caspases / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Enzyme Activation / physiology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Receptors, Interferon / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16187022.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon Regulatory Factor-1; 0 / Interferon Regulatory Factor-2; 0 / Receptors, Interferon; 77238-31-4 / Interferon-beta; EC 3.4.22.- / Caspases
  •  go-up   go-down


73. Di Rocco C, Chieffo D, Pettorini BL, Massimi L, Caldarelli M, Tamburrini G: Preoperative and postoperative neurological, neuropsychological and behavioral impairment in children with posterior cranial fossa astrocytomas and medulloblastomas: the role of the tumor and the impact of the surgical treatment. Childs Nerv Syst; 2010 Sep;26(9):1173-88
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative and postoperative neurological, neuropsychological and behavioral impairment in children with posterior cranial fossa astrocytomas and medulloblastomas: the role of the tumor and the impact of the surgical treatment.
  • INTRODUCTION: The aim of the present study was to prospectively investigate if a correlation might exist between preoperative and postoperative neurological conditions, neuroradiological/intraoperative findings and results of a complete neuropsychological evaluation in children with posterior fossa medulloblastomas and astrocytomas.
  • Neuropsychological assessment consisted of a battery of tests tailored on the patient's age, cognitive level, and level of cooperation.
  • For neuroradiological/intraoperative features, Intelligence Quotient (IQ) impairment was significantly correlated to the intraoperative evidence of tumor infiltration of the brainstem (p = 0.003), a severe hydrocephalus at diagnosis (p = 0.001) and the histological diagnosis of medulloblastoma (MB) (p = 0.002).
  • DISCUSSION: Our results support the hypothesis that when present, neuropsychological impairment is already present at diagnosis and that the most statistically significant factors, which might be related with cognitive deficits in the preoperative as well as in the postoperative period, are tumor infiltration of the brainstem, the severity of hydrocephalus, and a histological diagnosis of MB.
  • [MeSH-major] Astrocytoma / psychology. Cognition Disorders / psychology. Cranial Fossa, Posterior / surgery. Medulloblastoma / psychology. Skull Base Neoplasms / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552208.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


74. Toledano H, Goldberg Y, Kedar-Barnes I, Baris H, Porat RM, Shochat C, Bercovich D, Pikarsky E, Lerer I, Yaniv I, Abeliovich D, Peretz T: Homozygosity of MSH2 c.1906G--&gt;C germline mutation is associated with childhood colon cancer, astrocytoma and signs of Neurofibromatosis type I. Fam Cancer; 2009;8(3):187-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homozygosity of MSH2 c.1906G-->C germline mutation is associated with childhood colon cancer, astrocytoma and signs of Neurofibromatosis type I.
  • We report on a non-consanguineous Ashkenazi Jewish family with two affected siblings with features of NF1, colon cancer and astrocytoma at age 13 and 14.
  • Molecular and pathology studies were done on the tumor tissue and on genomic DNA of family members.
  • Tumor testing demonstrated a high degree of microsatellite instability (MSI analysis), expression of MLH1 and absence of expression of both MSH2 and MSH6 proteins.
  • [MeSH-major] Astrocytoma / genetics. Colonic Neoplasms / genetics. DNA-Binding Proteins / genetics. Germ-Line Mutation. MutS Homolog 2 Protein / genetics. Neurofibromatosis 1 / genetics
  • [MeSH-minor] Adolescent. Child. DNA Mutational Analysis. Female. Genetic Predisposition to Disease. Genetic Testing. Homozygote. Humans. Male. Pedigree

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19101824.001).
  • [ISSN] 1573-7292
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


75. Zeng N, Liu L, McCabe MG, Jones DT, Ichimura K, Collins VP: Real-time quantitative polymerase chain reaction (qPCR) analysis with fluorescence resonance energy transfer (FRET) probes reveals differential expression of the four ERBB4 juxtamembrane region variants between medulloblastoma and pilocytic astrocytoma. Neuropathol Appl Neurobiol; 2009 Aug;35(4):353-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time quantitative polymerase chain reaction (qPCR) analysis with fluorescence resonance energy transfer (FRET) probes reveals differential expression of the four ERBB4 juxtamembrane region variants between medulloblastoma and pilocytic astrocytoma.
  • AIMS: We report a comparative study on the mRNA expression of ErbB receptor tyrosine kinases, and in particular ERBB4 transcript variants, in two common paediatric brain tumours: medulloblastoma (MB) and pilocytic astrocytoma (PA).
  • [MeSH-major] Astrocytoma / metabolism. Brain / metabolism. Brain Neoplasms / metabolism. Medulloblastoma / metabolism. Receptor, Epidermal Growth Factor / metabolism

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5346-57 [14614020.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33334-41 [12807903.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8132-6 [8058768.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1813-21 [7538656.001]
  • [Cites] EMBO J. 1995 Sep 1;14(17):4267-75 [7556068.001]
  • [Cites] Am J Pathol. 1996 Feb;148(2):549-58 [8579117.001]
  • [Cites] EMBO J. 1996 May 15;15(10):2452-67 [8665853.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):1065-72 [8806696.001]
  • [Cites] Mol Cell Biol. 1996 Oct;16(10):5276-87 [8816440.001]
  • [Cites] J Biol Chem. 1996 Nov 29;271(48):30897-903 [8940074.001]
  • [Cites] EMBO J. 1997 Apr 1;16(7):1647-55 [9130710.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3272-80 [9242460.001]
  • [Cites] J Biol Chem. 1997 Oct 17;272(42):26761-8 [9334263.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3932-41 [9731505.001]
  • [Cites] J Pathol. 1998 Jul;185(3):236-45 [9771476.001]
  • [Cites] Oncogene. 1998 Oct 15;17(15):1949-57 [9788438.001]
  • [Cites] Oncogene. 1999 Apr 22;18(16):2607-15 [10353604.001]
  • [Cites] J Cell Biol. 2004 Nov 8;167(3):469-78 [15534001.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1384-93 [15735025.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):19777-83 [15746097.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6764-72 [16061658.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2006 Mar 5;141B(2):142-8 [16402353.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6412-20 [16778220.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):549-61 [16783165.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 [16829981.001]
  • [Cites] Histopathology. 2006 Jul;49(1):92-3 [16842254.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Aug;65(8):769-75 [16896310.001]
  • [Cites] Cell. 2006 Oct 6;127(1):185-97 [17018285.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]
  • [Cites] Oncogene. 2006 Nov 23;25(55):7267-73 [16878160.001]
  • [Cites] Hum Mol Genet. 2007 Jan 15;16(2):129-41 [17164265.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Oncogene. 2008 Mar 27;27(14):2097-108 [17934521.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5315-22 [10537315.001]
  • [Cites] J Biol Chem. 2000 Mar 24;275(12):8641-9 [10722704.001]
  • [Cites] J Biol Chem. 2000 Apr 7;275(14):10379-87 [10744726.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4217-25 [11106235.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):217-24 [11252897.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):288-94 [11391800.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(13):4265-75 [11390655.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2179-81 [11679632.001]
  • [Cites] J Pathol. 2002 Jan;196(1):17-25 [11748637.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6318-23 [11741961.001]
  • [Cites] Nature. 2003 Feb 13;421(6924):756-60 [12610629.001]
  • [Cites] Mol Cell. 2003 Feb;11(2):495-505 [12620236.001]
  • [Cites] J Clin Pathol. 2003 Apr;56(4):300-4 [12663644.001]
  • [Cites] Neuron. 2003 Apr 10;38(1):9-12 [12691659.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3764-74 [12839972.001]
  • [Cites] J Pathol. 2003 Jul;200(3):290-7 [12845624.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):758-65 [12866037.001]
  • [Cites] Exp Cell Res. 2004 Apr 1;294(2):469-79 [15023535.001]
  • (PMID = 19017278.001).
  • [ISSN] 1365-2990
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / CRUK/ A6618; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / ERBB4 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3; EC 2.7.10.1 / Receptor, ErbB-4; EC 3.4.- / Peptide Hydrolases
  • [Other-IDs] NLM/ PMC2705759; NLM/ UKMS4066
  •  go-up   go-down


76. Meini A, Sticozzi C, Massai L, Palmi M: A nitric oxide/Ca(2+)/calmodulin/ERK1/2 mitogen-activated protein kinase pathway is involved in the mitogenic effect of IL-1beta in human astrocytoma cells. Br J Pharmacol; 2008 Apr;153(8):1706-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A nitric oxide/Ca(2+)/calmodulin/ERK1/2 mitogen-activated protein kinase pathway is involved in the mitogenic effect of IL-1beta in human astrocytoma cells.
  • EXPERIMENTAL APPROACH: In this study we used human astrocytoma U-373MG cells to investigate the role of nitric oxide (NO), intracellular Ca(2+) concentration ([Ca(2+)](i)), and extracellular signal-regulated protein kinase (ERK) in the signalling pathway mediating IL-1beta-induced astrocyte proliferation.
  • Pretreatment with the nonspecific NOS inhibitor, N-omega-nitro-l-arginine methyl ester (L-NAME) or the selective iNOS inhibitor, N-[[3-(aminomethyl)phenyl]methyl]-ethanimidamide dihydrochloride (1400W), antagonized ERK activation and cell proliferation induced by IL-1beta.
  • [MeSH-minor] Astrocytoma / metabolism. Calcium / metabolism. Calmodulin / metabolism. Cell Proliferation / drug effects. Cells, Cultured. Dose-Response Relationship, Drug. Humans. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Mitosis / physiology. Nitric Oxide / metabolism. Time Factors

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Korean J Ophthalmol. 2003 Jun;17(1):1-6 [12882501.001]
  • [Cites] J Neurosci Res. 2007 Jun;85(8):1694-703 [17465018.001]
  • [Cites] Eur J Neurosci. 2004 Jan;19(2):479-84 [14725643.001]
  • [Cites] J Neurosci. 2004 Mar 17;24(11):2837-45 [15028778.001]
  • [Cites] Curr Mol Med. 2004 Mar;4(2):193-205 [15032713.001]
  • [Cites] Prog Neurobiol. 2004 Feb;72(2):111-27 [15063528.001]
  • [Cites] Trends Neurosci. 2004 May;27(5):238-40 [15111002.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):19936-47 [14996842.001]
  • [Cites] J Cell Sci. 2004 Sep 15;117(Pt 20):4727-37 [15331636.001]
  • [Cites] Med Sci Monit. 2004 Sep;10(9):BR325-30 [15328477.001]
  • [Cites] J Cell Biol. 1982 Aug;94(2):325-34 [6980885.001]
  • [Cites] Science. 1985 Apr 26;228(4698):497-9 [3872478.001]
  • [Cites] Lymphokine Res. 1987 Spring;6(2):83-91 [3495709.001]
  • [Cites] Brain Res. 1988 Feb 1;466(2):201-10 [3359311.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Mar 30;167(3):1242-8 [2157429.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 1992;119:67-121 [1604156.001]
  • [Cites] J Neurol Sci. 1992 Aug;111(1):92-103 [1403003.001]
  • [Cites] FEBS Lett. 2000 Apr 28;472(2-3):203-7 [10788611.001]
  • [Cites] Br J Pharmacol. 2000 Jun;130(4):891-9 [10864897.001]
  • [Cites] J Neurosci. 2000 Dec 15;20(24):8980-6 [11124973.001]
  • [Cites] Br J Pharmacol. 2001 Apr;132(7):1531-41 [11264247.001]
  • [Cites] Circulation. 2001 Sep 18;104(12 Suppl 1):I344-9 [11568080.001]
  • [Cites] Mol Neurobiol. 2002 Apr;25(2):133-47 [11936556.001]
  • [Cites] Cell Signal. 2002 Aug;14(8):649-54 [12020764.001]
  • [Cites] J Mol Cell Cardiol. 2002 May;34(5):583-96 [12056861.001]
  • [Cites] Neurosignals. 2002 Jul-Aug;11(4):175-90 [12393944.001]
  • [Cites] Neuroscientist. 2003 Feb;9(1):10-22 [12580336.001]
  • [Cites] Eur J Neurosci. 2003 Feb;17(4):692-700 [12603259.001]
  • [Cites] Nature. 1993 Jan 28;361(6410):315-25 [8381210.001]
  • [Cites] Prog Brain Res. 1992;94:353-65 [1337615.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Mar 15;191(2):327-34 [7681665.001]
  • [Cites] Neurosci Lett. 1994 Jun 20;174(2):123-6 [7526282.001]
  • [Cites] Nature. 1995 Aug 10;376(6540):524-7 [7637786.001]
  • [Cites] Eur J Pharmacol. 1995 Jul 25;281(1):97-9 [8566125.001]
  • [Cites] J Neurochem. 1996 Apr;66(4):1496-503 [8627304.001]
  • [Cites] Am J Pathol. 1996 Mar;148(3):889-96 [8774143.001]
  • [Cites] Br J Pharmacol. 1996 Aug;118(7):1705-10 [8842435.001]
  • [Cites] N Engl J Med. 1998 Jan 29;338(5):278-85 [9445407.001]
  • [Cites] Science. 1998 May 15;280(5366):1082-6 [9582122.001]
  • [Cites] Eur J Neurosci. 2005 May;21(9):2347-60 [15932594.001]
  • [Cites] Curr Opin Investig Drugs. 2005 Jul;6(7):700-3 [16044665.001]
  • [Cites] Nitric Oxide. 2006 May;14(3):238-46 [16300973.001]
  • [Cites] Eur J Neurosci. 2006 Apr;23(7):1690-700 [16623825.001]
  • [Cites] J Neurochem. 2006 Jun;97(6):1676-89 [16805776.001]
  • [Cites] Diabetes. 2006 Sep;55(9):2455-62 [16936193.001]
  • [Cites] Glia. 2003 Oct;44(1):47-56 [12951656.001]
  • (PMID = 18297103.001).
  • [ISSN] 0007-1188
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calmodulin; 0 / Interleukin-1beta; 31C4KY9ESH / Nitric Oxide; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2438268
  •  go-up   go-down


77. Pu P, Zhang Z, Kang C, Jiang R, Jia Z, Wang G, Jiang H: Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther; 2009 Apr;16(4):351-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth.
  • Increasing evidence suggests that aberrant activation of Wnt signaling is involved in tumor development and progression.
  • Our earlier study on gene expression profile in human gliomas by microarray found that some members of Wnt family were overexpressed.
  • To further investigate the involvement of Wnt signaling in gliomas, the expression of core components of Wnt signaling cascade in 45 astrocytic glioma specimens with different tumor grades was examined by reverse transcription-PCR and immunohistochemistry.
  • Wnt2, Wnt5a, frizzled2 and beta-catenin were overexpressed in gliomas.
  • Knockdown of Wnt2 and its key mediator beta-catenin in the canonical Wnt pathway by siRNA in human U251 glioma cells inhibited cell proliferation and invasive ability, and induced apoptotic cell death.
  • Furthermore, treating the nude mice carrying established subcutaneous U251 gliomas with siRNA targeting Wnt2 and beta-catenin intratumorally also delayed the tumor growth.
  • In conclusion, the canonical Wnt pathway is of critical importance in the gliomagenesis and intervention of this pathway may provide a new therapeutic approach for malignant gliomas.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Female. Humans. Mice. Neoplasm Invasiveness. Neoplasm Transplantation. RNA Interference. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Glioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949017.001).
  • [ISSN] 1476-5500
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Wnt2 Protein; 0 / beta Catenin
  •  go-up   go-down


78. Hashioka S, Klegeris A, Schwab C, McGeer PL: Interferon-gamma-dependent cytotoxic activation of human astrocytes and astrocytoma cells. Neurobiol Aging; 2009 Dec;30(12):1924-35
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-gamma-dependent cytotoxic activation of human astrocytes and astrocytoma cells.
  • Astrocytes and microglia become activated in a broad spectrum of inflammatory neurodegenerative diseases.
  • To investigate the neurotoxic potential of human astrocytes, we exposed them and human astrocytic U-373 MG cells to a variety of inflammatory stimulants.
  • Other powerful inflammatory stimulants such as lipopolysaccharide (0.5mug/ml), tumor necrosis factor-alpha (10ng/ml) and interleukin-1beta (10ng/ml), alone or in combination, were without effect.
  • Finally, using human postmortem material, we showed sharp upregulation of the IFNGR on activated astrocytes in affected areas in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis.
  • These findings suggest that activated astrocytes may become neurotoxic when stimulated by IFN-gamma and may therefore exacerbate the pathology in a spectrum of neurodegenerative diseases.
  • [MeSH-major] Astrocytes / physiology. Astrocytoma / physiopathology. Cell Survival. Interferon-gamma / metabolism
  • [MeSH-minor] Alzheimer Disease / metabolism. Amyotrophic Lateral Sclerosis / metabolism. Brain / immunology. Brain / physiopathology. Cell Line, Tumor. Humans. Janus Kinases / antagonists & inhibitors. Janus Kinases / metabolism. Lipopolysaccharides / metabolism. Multiple Sclerosis / metabolism. Parkinson Disease / metabolism. Receptors, Interferon / metabolism. Signal Transduction. Tumor Necrosis Factor-alpha / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18375019.001).
  • [ISSN] 1558-1497
  • [Journal-full-title] Neurobiology of aging
  • [ISO-abbreviation] Neurobiol. Aging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipopolysaccharides; 0 / Receptors, Interferon; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma; EC 2.7.10.2 / Janus Kinases
  •  go-up   go-down


79. Szeifert GT, Kondziolka D, Atteberry DS, Salmon I, Rorive S, Levivier M, Lunsford LD: Radiosurgical pathology of brain tumors: metastases, schwannomas, meningiomas, astrocytomas, hemangioblastomas. Prog Neurol Surg; 2007;20:91-105
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgical pathology of brain tumors: metastases, schwannomas, meningiomas, astrocytomas, hemangioblastomas.
  • Systematic human pathological background to brain tumor radiosurgery explaining biological and pathophysiological effects of focused irradiation barely exists.
  • [MeSH-minor] Astrocytoma / pathology. Astrocytoma / surgery. Hemangioblastoma / pathology. Hemangioblastoma / surgery. Humans. Meningioma / pathology. Meningioma / surgery. Neurilemmoma / pathology. Neurilemmoma / surgery. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317979.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  •  go-up   go-down


80. Meije Y, Lizasoain M, García-Reyne A, Martínez P, Rodríguez V, López-Medrano F, Juan RS, Lalueza A, Aguado JM: Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. Clin Infect Dis; 2010 Jun 15;50(12):e73-6
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review.
  • Temozolomide chemotherapy has become part of the therapy used to treat glioblastoma multiforme and refractory anaplastic astrocytoma.
  • We report 2 cases of cytomegalovirus disease that occurred in patients receiving temozolomide therapy and review 4 additional cases reported in the literature.

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20455691.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 16
  •  go-up   go-down


81. Soichi O, Masanori N, Hideo T, Kazunori A, Nobuya I, Jun-ichi K: Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas. Neurosurgery; 2007 Apr;60(4):707-14; discussion 714
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: To determine whether or not ABCA2 can distinguish oligodendrogliomas from astrocytic tumors, the authors investigated the expression of ABCA2 in a panel of 55 glioma tissues (13 oligodendrogliomas, nine anaplastic oligodendrogliomas, 12 anaplastic astrocytomas, and 21 glioblastomas) using real-time reverse-transcriptase polymerase chain reaction analysis, immunoblot analysis, and immunohistochemistry analysis.
  • RESULTS: The relative expression level of ABCA2 messenger ribonucleic acid determined by real-time quantitative polymerase chain reaction is significantly higher (by a factor of five) in oligodendroglioma than in anaplastic astrocytoma or glioblastoma.
  • In immunohistochemical analysis, ABCA2 exhibited remarkable immunopositivity in 11 out of 13 oligodendrogliomas showing a granular pattern in the cytoplasm of tumor cells.
  • However, ABCA2 was completely negative in most anaplastic astrocytomas (75%) and glioblastomas (76%).
  • However, Olig2 was strongly positive in most anaplastic astrocytomas (83%) and glioblastomas (71%).
  • Although there was no difference in the detection of oligodendroglial tumors, the specificity (negative in astrocytic tumor) was significantly higher in ABCA2 than in Olig2.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Neoplasm Proteins / metabolism. Oligodendroglioma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415208.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCA2 protein, human; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


82. Rousseau A, Nutt CL, Betensky RA, Iafrate AJ, Han M, Ligon KL, Rowitch DH, Louis DN: Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropathol Exp Neurol; 2006 Dec;65(12):1149-56
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
  • The phenotypic heterogeneity of astrocytic and oligodendroglial tumor cells complicates establishing accurate diagnostic criteria, and lineage-specific markers would facilitate diagnosis of glioma subtypes.
  • Based on data from the literature and from expression microarrays, we selected molecules relevant to gliogenesis and glial lineage specificity and then used immunohistochemistry to assess expression of these molecules in 55 diffuse gliomas, including 8 biphasic oligoastrocytomas, 21 oligodendrogliomas (all with 1p/19qloss), 21 astrocytomas, and 5 glioblastomas.
  • For the astrocytic lineage markers (GFAP, YKL-40, and ApoE), GFAP expression was significantly higher in the astrocytic component of oligoastrocytomas compared with the oligodendroglial part; similar patterns were detected for YKL-40 and ApoE, although the differences were not significant.
  • GFAP, YKL-40, and ApoE reliably distinguished grade II-III oligodendrogliomas from grade II-IV astrocytomas (p < 0.0001, p = 0.002, and p < 0.0001, respectively).
  • Among the oligodendroglial lineage markers (Olig2, Sox10, ASCL1, and NKX2-2), ASCL1 and NKX2-2 displayed significantly different immunostaining between oligodendrogliomas and astrocytomas (p = 0.017 and 0.004, respectively), but none clearly differentiated between the 2 glial populations of oligoastrocytomas.
  • In addition to GFAP, therefore, YKL-40, ApoE, ASCL1, and NKX2-2 represent promising tumor cell markers to distinguish oligodendrogliomas from astrocytomas.
  • [MeSH-major] Astrocytes / pathology. Biomarkers, Tumor / metabolism. Brain Neoplasms / diagnosis. Cell Lineage / genetics. Glioma / diagnosis. Oligodendroglia / pathology
  • [MeSH-minor] Adipokines. Apolipoproteins E / analysis. Apolipoproteins E / metabolism. Astrocytoma / diagnosis. Astrocytoma / genetics. Astrocytoma / metabolism. Basic Helix-Loop-Helix Transcription Factors / analysis. Basic Helix-Loop-Helix Transcription Factors / metabolism. Diagnosis, Differential. Glial Fibrillary Acidic Protein / analysis. Glial Fibrillary Acidic Protein / metabolism. Glycoproteins / analysis. Glycoproteins / metabolism. Homeodomain Proteins / analysis. Homeodomain Proteins / metabolism. Humans. Immunohistochemistry. Lectins. Oligodendroglioma / diagnosis. Oligodendroglioma / genetics. Oligodendroglioma / metabolism. Predictive Value of Tests. Transcription Factors / analysis. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17146289.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 57683; United States / NCI NIH HHS / CA / CA 95616
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ASCL1 protein, human; 0 / Adipokines; 0 / Apolipoproteins E; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / CHI3L1 protein, human; 0 / Glial Fibrillary Acidic Protein; 0 / Glycoproteins; 0 / Homeodomain Proteins; 0 / Lectins; 0 / Nkx-2.2 homedomain protein; 0 / Transcription Factors; 0 / apolipoprotein E1
  •  go-up   go-down


83. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol; 2006 May;111(5):483-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression.
  • However, little information exists about its role in CNS astrocytic tumors.
  • In this study, 188 astrocytic tumors (30 diffuse astrocytomas, 43 anaplastic astrocytomas, and 115 glioblastomas) were investigated using immunohistochemistry with an anti-podoplanin antibody, YM-1.
  • In 11 of 43 anaplastic astrocytomas (25.6%) and in 54 of 115 glioblastomas (47.0%), podoplanin was expressed on the surface of anaplastic astrocytoma cells and glioblastoma cells, especially around necrotic areas and proliferating endothelial cells.
  • On the other hand, podoplanin expression was not observed in diffuse astrocytoma (0/30: 0%).
  • Furthermore, we investigated the expression of podoplanin using quantitative real-time PCR and Western blot analysis in 54 frozen astrocytic tumors (6 diffuse astrocytomas, 14 anaplastic astrocytomas, and 34 glioblastomas).
  • Podoplanin mRNA and protein expression were markedly higher in glioblastomas than in anaplastic astrocytomas.
  • These data suggest that podoplanin expression might be associated with malignancy of astrocytic tumors.
  • [MeSH-major] Astrocytoma / metabolism. Central Nervous System Neoplasms / metabolism. Glioblastoma / metabolism. Membrane Glycoproteins / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Blotting, Western. Disease Progression. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596424.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / PDPN protein, human; 0 / RNA, Messenger
  •  go-up   go-down


84. Yamaguchi F, Takahashi H, Teramoto A: Photodiagnosis for frameless stereotactic biopsy of brain tumor. Photodiagnosis Photodyn Ther; 2007 Mar;4(1):71-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodiagnosis for frameless stereotactic biopsy of brain tumor.
  • In this study, we investigated the usefulness of fluorescence in determining the existence of tumor components in obtained tissues.
  • The final pathological diagnoses were of three glioblastomas, one astrocytoma grade 3, and two malignant lymphomas.
  • One case was initially thought to be gliosis on rapid pathological diagnosis, but the final pathological diagnosis reached by examination of a permanent HE stained section was astrocytoma grade 3.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25047195.001).
  • [ISSN] 1572-1000
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


85. Balducci M, Apicella G, Manfrida S, Mangiola A, Fiorentino A, Azario L, D'Agostino GR, Frascino V, Dinapoli N, Mantini G, Albanese A, de Bonis P, Chiesa S, Valentini V, Anile C, Cellini N: Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report. Strahlenther Onkol; 2010 Oct;186(10):558-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report.
  • PURPOSE: To assess survival, local control and toxicity using fractionated stereotactic conformal radiotherapy (FSCRT) boost and temozolomide in high-grade gliomas (HGGs).
  • PATIENTS AND METHODS: Patients affected by HGG, with a CTV(1)(clinical target volume, representing tumor bed ± residual tumor + a margin of 5 mm) ≤ 8 cm were enrolled into this phase II study.
  • RESULTS: 41 patients (36 with glioblastoma multiforme [GBM] and five with anaplastic astrocytoma [AA]) were enrolled; RTOG neurological toxicities G1-2 and G3 were 12% and 3%, respectively.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Glioma / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Actuarial Analysis. Adult. Aged. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiosurgery / adverse effects. Radiosurgery / methods. Survival Rate

  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20936460.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


86. Shirai K, Suzuki Y, Okamoto M, Wakatsuki M, Noda SE, Takahashi T, Ishiuchi S, Hasegawa M, Nakazato Y, Nakano T: Influence of histological subtype on survival after combined therapy of surgery and radiation in WHO grade 3 glioma. J Radiat Res; 2010;51(5):589-94
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of histological subtype on survival after combined therapy of surgery and radiation in WHO grade 3 glioma.
  • World Health Organization (WHO) grade 3 glioma is one of the common brain tumors and has three main histological subtypes, including anaplastic astrocytoma (AA), anaplastic oligoastrocytoma (AOA) and anaplastic oligodendroglioma (AO).
  • In this study, 68 patients with histologically proven WHO grade 3 glioma, consecutively received postoperative radiotherapy at the Gunma University Hospital, Japan, between 1983 and 2005, were investigated to assess the impact of histological subtype on the survival.
  • Univariate analysis showed that the histological subtype (P < 0.01) and extent of surgery (P < 0.01) were significant prognostic factors for survival.
  • Multivariate analysis demonstrated that histological subtype, age and extent of surgery were the significant independent variable for survival (P < 0.01, P < 0.01 and P = 0.04).
  • In our study, histological subtype was one of the most important prognostic factors of WHO grade 3 glioma.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Oligodendroglioma / radiotherapy

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20921826.001).
  • [ISSN] 1349-9157
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


87. Chou CH, Lieu AS, Wu CH, Chang LK, Loh JK, Lin RC, Chen WJ, Liao HD, Fu WS, Chang CS, Lin CC, Hsu CM, Chio CC, Howng SL, Hong YR: Differential expression of hedgehog signaling components and Snail/E-cadherin in human brain tumors. Oncol Rep; 2010 Nov;24(5):1225-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our results also indicated that Snail and E-cadherin showed opposing expression in malignant tumors (high grade astrocytoma and metastasis).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878114.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cadherins; 0 / Hedgehog Proteins; 0 / Transcription Factors; 0 / snail family transcription factors
  •  go-up   go-down


88. Bozinov O, Kalk JM, Krayenbühl N, Woernle CM, Sure U, Bertalanffy H: Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas. Neurol Med Chir (Tokyo); 2010;50(8):617-21
Hazardous Substances Data Bank. TENIPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas.
  • The IL-13Ralpha2 gene encodes for a 65 kDa protein that forms one of the subunits of the interleukin-13 (IL-13) receptor.
  • This gene is highly expressed in various types of human tumors including malignant gliomas.
  • The expression level of IL-13Ralpha2 was examined in a total of 45 tissue samples of anaplastic astrocytomas (AAs) World Health Organization (WHO) grade III, glioblastomas (GBMs) WHO grade IV, and first-recurrent glioblastomas (frGBMs) after treatment with radiation and chemotherapy.
  • The expression level of IL-13Ralpha2 (15 fold) was significantly reduced in frGBMs compared to the primary GBMs (p = 0.014), and significantly reduced by more than 15 fold (p = 0.003) in all untreated malignant astrocytomas (AAs and GBMs) compared with treated frGBMs.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Interleukin-13 Receptor alpha2 Subunit / metabolism. Neoplasm Recurrence, Local / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20805641.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Actins; 0 / Exotoxins; 0 / IL13-PE38QQR; 0 / Immunotoxins; 0 / Interleukin-13; 0 / Interleukin-13 Receptor alpha2 Subunit; 0S726V972K / Nimustine; 63231-63-0 / RNA; 957E6438QA / Teniposide
  •  go-up   go-down


89. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G: Molecular diagnostics of gliomas: state of the art. Acta Neuropathol; 2010 Nov;120(5):567-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnostics of gliomas: state of the art.
  • Modern neuropathology serves a key function in the multidisciplinary management of brain tumor patients.
  • Owing to the recent advancements in molecular neurooncology, the neuropathological assessment of brain tumors is no longer restricted to provide information on a tumor's histological type and malignancy grade, but may be complemented by a growing number of molecular tests for clinically relevant tissue-based biomarkers.
  • This article provides an overview and critical appraisal of the types of genetic and epigenetic aberrations that have gained significance in the molecular diagnostics of gliomas, namely deletions of chromosome arms 1p and 19q, promoter hypermethylation of the O6-methylguanine-methyl-transferase (MGMT) gene, and the mutation status of the IDH1 and IDH2 genes.
  • In addition, the frequent oncogenic aberration of BRAF in pilocytic astrocytomas may serve as a novel diagnostic marker and therapeutic target.
  • Finally, this review will summarize recent mechanistic insights into the molecular alterations underlying treatment resistance in malignant gliomas and outline the potential of genome-wide profiling approaches for increasing our repertoire of clinically useful glioma markers.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Epigenomics / methods. Glioma / diagnosis. Glioma / genetics. Pathology, Molecular / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1995 Jul 15;55(14):3140-8 [7606735.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3310-5 [9779706.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Jun;58(6):606-12 [10374751.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):379-85 [15455350.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):161-81 [15674476.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):7-16 [15720813.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1462-6 [15746047.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Histopathology. 2008 Nov;53(5):578-87 [18983467.001]
  • [Cites] Semin Immunol. 2008 Oct;20(5):267-75 [18539480.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Feb 6;379(2):434-9 [19116135.001]
  • [Cites] Hum Mutat. 2009 Jan;30(1):7-11 [19117336.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] Am J Pathol. 2009 Apr;174(4):1149-53 [19246647.001]
  • [Cites] Science. 2009 Apr 10;324(5924):261-5 [19359588.001]
  • [Cites] J Clin Neurosci. 2009 Jun;16(6):748-54 [19324552.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):253-60 [16723632.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3431-7 [16849758.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):433-43 [16931583.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4412-7 [16983109.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1891-7 [16986124.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2038-45 [17404084.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2368-76 [17285580.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1470-5 [17442989.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6002-7 [19755387.001]
  • [Cites] Clin Cancer Res. 2009 Nov 1;15(21):6683-93 [19861461.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Dec 18;390(3):547-51 [19818334.001]
  • [Cites] Neurology. 2009 Nov 24;73(21):1792-5 [19933982.001]
  • [Cites] J Clin Oncol. 2009 Dec 1;27(34):5743-50 [19805672.001]
  • [Cites] J Neuropathol Exp Neurol. 2009 Dec;68(12):1319-25 [19915484.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5881-6 [19901104.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5874-80 [19901110.001]
  • [Cites] Nature. 2009 Dec 10;462(7274):739-44 [19935646.001]
  • [Cites] Pediatr Blood Cancer. 2010 Feb;54(2):228-37 [19856394.001]
  • [Cites] Nat Rev Neurol. 2010 Jan;6(1):39-51 [19997073.001]
  • [Cites] Cancer Cell. 2010 Jan 19;17(1):98-110 [20129251.001]
  • [Cites] Neuro Oncol. 2010 Jan;12(1):49-57 [20150367.001]
  • [Cites] Neuro Oncol. 2010 Feb;12(2):116-21 [20150378.001]
  • [Cites] J Exp Med. 2010 Feb 15;207(2):339-44 [20142433.001]
  • [Cites] Hum Mutat. 2010 Mar;31(3):E1186-99 [20077503.001]
  • [Cites] Clin Cancer Res. 2010 Mar 1;16(5):1597-604 [20160062.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Mar;95(3):1274-8 [19915015.001]
  • [Cites] Cancer Cell. 2010 Mar 16;17(3):225-34 [20171147.001]
  • [Cites] Acta Neuropathol. 2010 Apr;119(4):501-7 [20131059.001]
  • [Cites] Blood. 2010 Apr 8;115(14):2749-54 [20097881.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Pathol. 2001 May;194(1):81-7 [11329145.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):410-8 [11567815.001]
  • [Cites] Nucleic Acids Res. 2002 Jun 15;30(12):e57 [12060695.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4307-15 [12154034.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1276-84 [12599236.001]
  • [Cites] Lab Invest. 2003 Mar;83(3):419-28 [12649342.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4247-54 [14519652.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6962-70 [14583498.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5370-9 [14614022.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):920-7 [14871821.001]
  • [Cites] Pathol Oncol Res. 2004;10(1):17-21 [15029256.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):397-405 [14990981.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):296-307 [15057289.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):121-30 [15193024.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8602-6 [2236070.001]
  • [Cites] Acta Neuropathol. 2009 Jun;117(6):653-6 [19340432.001]
  • [Cites] Oncogene. 2009 May 21;28(20):2119-23 [19363522.001]
  • [Cites] Int J Cancer. 2009 Jul 15;125(2):353-5 [19378339.001]
  • [Cites] Expert Opin Biol Ther. 2009 Aug;9(8):1087-98 [19591631.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4622-9 [19584161.001]
  • [Cites] Acta Neuropathol. 2009 Sep;118(3):401-5 [19543740.001]
  • [Cites] Neuro Oncol. 2009 Aug;11(4):341-7 [19435942.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4150-4 [19636000.001]
  • [Cites] Acta Neuropathol. 2009 Oct;118(4):469-74 [19554337.001]
  • [Cites] Brain Pathol. 2009 Oct;19(4):661-71 [19744038.001]
  • [Cites] Cancer Sci. 2009 Oct;100(10):1996-8 [19765000.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] Int J Cancer. 2005 Oct 20;117(1):95-103 [15880582.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1364-8 [16170028.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Nov;64(11):948-55 [16254489.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Cancer Treat Rev. 2006 Apr;32(2):74-89 [16488082.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1759-65 [16541434.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3987-91 [16618716.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Cancer. 2010 Apr 15;116(8):1844-6 [20151424.001]
  • [Cites] Nature. 2010 Apr 15;464(7291):993-8 [20393554.001]
  • [Cites] Brain Pathol. 2010 Jan;20(1):245-54 [19903171.001]
  • [Cites] Brain Pathol. 2010 Mar;20(2):298-300 [19744125.001]
  • [Cites] Cancer Cell. 2010 May 18;17(5):510-22 [20399149.001]
  • [Cites] Neurology. 2010 Jun 8;74(23):1886-90 [20427748.001]
  • [Cites] Curr Opin Genet Dev. 2010 Jun;20(3):324-9 [20304625.001]
  • [Cites] J Clin Oncol. 2010 Jun 20;28(18):3061-8 [20479398.001]
  • [Cites] Mol Diagn Ther. 2010 Jun 1;14(3):163-9 [20560678.001]
  • [Cites] Neuropathol Appl Neurobiol. 2010 Jun;36(4):356-8 [20202118.001]
  • [Cites] Acta Neuropathol. 2010 Aug;120(2):261-7 [20514489.001]
  • [Cites] J Clin Oncol. 2010 Jul 1;28(19):3182-90 [20516456.001]
  • [Cites] Cancer Res. 2010 Jul 1;70(13):5457-64 [20530668.001]
  • [Cites] J Neuropathol Exp Neurol. 2010 Jul;69(7):729-36 [20535033.001]
  • [Cites] J Mol Diagn. 2010 Jul;12(4):487-92 [20431032.001]
  • [Cites] J Natl Cancer Inst. 2010 Jul 7;102(13):932-41 [20513808.001]
  • [Cites] Biochem Biophys Res Commun. 2010 Jun 25;397(2):127-30 [20510884.001]
  • [Cites] J Pediatr Hematol Oncol. 2010 Aug;32(6):511-4 [20463608.001]
  • [Cites] J Neurooncol. 2010 Sep;99(2):209-15 [20174854.001]
  • [Cites] J Neurooncol. 2010 Dec;100(3):489-90 [20449628.001]
  • [Cites] Int J Cancer. 2011 Mar 1;128(5):1095-103 [20473936.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4010-5 [17483311.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2288-94 [17538175.001]
  • [Cites] Radiother Oncol. 2007 Jun;83(3):333-9 [17512071.001]
  • [Cites] J Mol Diagn. 2007 Jul;9(3):368-81 [17591937.001]
  • [Cites] Lab Invest. 2007 Oct;87(10):1055-65 [17700563.001]
  • [Cites] Acta Neuropathol. 2007 Nov;114(5):443-58 [17805551.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6933-7 [18056167.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Jan;67(1):1-15 [18091559.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):488-93 [18223223.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] J Chemother. 2008 Apr;20(2):263-8 [18467255.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):360-9 [18371182.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3015-24 [18565887.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):332-7 [18556773.001]
  • [Cites] J Neurooncol. 2008 Sep;89(2):211-8 [18458820.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4859-68 [18676759.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]
  • [Cites] Expert Rev Vaccines. 2008 Sep;7(7):977-85 [18767947.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • (PMID = 20714900.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2955236
  •  go-up   go-down


90. Lawal AO, Ellis E: Differential sensitivity and responsiveness of three human cell lines HepG2, 1321N1 and HEK 293 to cadmium. J Toxicol Sci; 2010 Aug;35(4):465-78
Hazardous Substances Data Bank. N-ACETYLCYSTEINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this the present study, the toxic effect of 5, 10 and 50 microM of Cd chloride was compared in three human cell lines; a human hepatoma cell line HepG2, a human astrocytoma cell line 1321N1, and a human embryonic kidney cell HEK 293.
  • ROS levels significantly increase and GSH/GSSG ratio significantly decrease in all the three cell lines after Cd exposure, but these effects were attenuated by the presence of N-acetylcysteine (NAC).
  • [MeSH-minor] Acetylcysteine / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Glutathione / pharmacology. HEK293 Cells. Hep G2 Cells. Humans. Reactive Oxygen Species / pharmacology

  • Hazardous Substances Data Bank. CADMIUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686333.001).
  • [ISSN] 1880-3989
  • [Journal-full-title] The Journal of toxicological sciences
  • [ISO-abbreviation] J Toxicol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; GAN16C9B8O / Glutathione; J6K4F9V3BA / Cadmium Chloride; WYQ7N0BPYC / Acetylcysteine
  •  go-up   go-down


91. Srinivas BH, Uppin MS, Panigrahi MK, Vijaya Saradhi M, Jyotsna Rani Y, Challa S: Pleomorphic xanthoastrocytoma of the pineal region. J Clin Neurosci; 2010 Nov;17(11):1439-41
Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic xanthoastrocytomas are indolent, astrocytic tumors usually located in the superficial cerebral cortex.
  • We describe a patient with an astrocytic tumor arising in the pineal region that fulfilled all of the morphologic and immunohistochemical criteria of a pleomorphic xanthoastrocytoma.
  • To our knowledge, this is the first description of a pleomorphic xanthoastrocytoma located in the pineal region.
  • [MeSH-major] Astrocytoma / diagnosis. Pineal Gland / pathology. Pinealoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20655751.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


92. Pascual-Castroviejo I, Quiñones-Tapia D: [Spontaneous involution of frontal tumors in a patient with neurofibromatosis type 1]. Rev Neurol; 2010 Aug 16;51(4):213-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Involución espontánea de tumores frontales en un paciente con neurofibromatosis tipo 1.
  • CASE REPORT: A girl with NF1 and cerebral tumors, probably astrocytomas, with similar neuroimaging characteristics, was studied by magnetic resonance (MR) and MR spectroscopy between 29 months and 6- years of age.
  • The frontal tumors (one on each hemisphere) did not change size in the MR studies done during the first three and a half years of life, but, at six years, the right frontal lobe tumor had apparently disappeared and the left frontal lobe tumor had decreased in a 90% of its original size.
  • During the first three and half years of life, MR images did not demonstrate any optic tumor.
  • However, such a tumor appeared well developed when the MR study was performed at six years of age.
  • [MeSH-major] Brain Neoplasms / etiology. Frontal Lobe. Neoplasm Regression, Spontaneous. Neurofibromatosis 1 / complications


93. Wick W, Weller M: [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts]. Nervenarzt; 2010 Aug;81(8):928-30, 932-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts].
  • [Transliterated title] Anaplastische Gliome. Neuropathologie, molekulare Diagnostik und aktuelle Studienkonzepte.
  • According to the current WHO classification anaplastic gliomas comprise pure astrocytomas and oligodendrogliomas and mixed tumors.
  • This review summarizes findings, discusses problems and defines new questions from the phase III trials on anaplastic gliomas.
  • Therefore, marker profiles should be included into the next WHO brain tumor classification.
  • The current standard of care for first-line treatment in anaplastic gliomas is radiotherapy or chemotherapy.
  • The next steps, e.g. within the international CATNON trial, are to define the role and optimal sequencing of combined modality treatment focusing on radiotherapy and temozolomide.
  • Inclusion in this trial is already based on the WHO grade and the 1p/19q status and not on the histopathological subtype.
  • Furthermore, anaplastic gliomas are an important group of brain tumors for developing future molecular targeted therapies and should therefore be in the main focus of academic and industrial drug development, which aims at improved efficacy and avoiding long-term side-effects.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Brain / pathology. Chromosome Deletion. Clinical Trials as Topic. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Cranial Irradiation. DNA Modification Methylases / genetics. DNA Mutational Analysis. DNA Repair Enzymes / genetics. Disease-Free Survival. Humans. Isocitrate Dehydrogenase / genetics. Promoter Regions, Genetic / genetics. Survival Rate. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2009 May;10 (5):459-66 [19269895.001]
  • [Cites] J Neurol. 2009 May;256(5):734-41 [19240962.001]
  • [Cites] Science. 2009 Apr 10;324(5924):261-5 [19359588.001]
  • [Cites] Cancer Res. 2009 May 15;69(10 ):4502-9 [19366800.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1210-6 [18248979.001]
  • [Cites] J Neurooncol. 2009 May;92(3):401-15 [19357966.001]
  • [Cites] J Clin Oncol. 2010 Apr 20;28(12 ):2051-7 [20308655.001]
  • [Cites] Nat Rev Neurol. 2010 Jan;6(1):39-51 [19997073.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):392-401 [16648043.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3276-84 [12947063.001]
  • [Cites] Neuro Oncol. 2008 Dec;10 (6):1019-24 [18676355.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5881-6 [19901104.001]
  • [Cites] J Clin Oncol. 2010 Apr 10;28(11):1963-72 [20231676.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):737-46 [19224764.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer Cell. 2010 May 18;17(5):510-22 [20399149.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14 (21):7068-73 [18981004.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3357-61 [17664483.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):257-9 [11958379.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5874-80 [19901110.001]
  • [Cites] Acta Neuropathol. 2009 Oct;118(4):469-74 [19554337.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):330-5 [18240930.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6933-7 [18056167.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Neurology. 2006 Jan 24;66(2):239-42 [16434662.001]
  • (PMID = 20635074.001).
  • [ISSN] 1433-0407
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


94. Merrell RT, Anderson SK, Meyer FB, Lachance DH: Seizures in patients with glioma treated with phenytoin and levetiracetam. J Neurosurg; 2010 Dec;113(6):1176-81
Hazardous Substances Data Bank. PIRACETAM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seizures in patients with glioma treated with phenytoin and levetiracetam.
  • OBJECT: Second-generation antiepileptic drugs (AEDs) are increasingly used in the care of patients with glioma.
  • This noninferiority analysis compares seizure outcomes and side effects in patients with glioma treated with phenytoin and levetiracetam monotherapy.
  • METHODS: The authors retrospectively reviewed the records of 500 consecutive patients with glioma who were treated in clinical trials from 2001 to 2008 at 3 Mayo Clinic campuses.
  • Seizure outcomes, defined by the occurrence of a second seizure, time to second seizure, and seizure frequency, along with AED side effects, were compared between cohorts treated with phenytoin or levetiracetam RESULTS: Seventy-six patients were identified, 25 treated with phenytoin and 51 with levetiracetam.
  • Sixty-four percent of the patients had a Grade 4 astrocytoma.
  • When adjusting for age, sex, type of seizure, type of glioma, and dosage using univariate and multivariate models, there were no differences between the treatment groups and none of these covariates were statistically significant for explaining the second seizure rates between treatment groups (all p values>0.05).
  • Additionally, 36% of the patients in the phenytoin group had dose adjustments unrelated to breakthrough seizures compared with only 10% in the levetiracetam group (p=0.010) CONCLUSIONS: In this study, patients with glioma treated with levetiracetam and phenytoin had similar seizure control.
  • Levetiracetam is a safe, effective, and preferred alternative for seizure management in patients with glioma.
  • [MeSH-major] Anticonvulsants / therapeutic use. Glioma / complications. Phenytoin / therapeutic use. Piracetam / analogs & derivatives. Seizures / drug therapy

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Seizures.
  • Hazardous Substances Data Bank. PHENYTOIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20560728.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 230447L0GL / etiracetam; 6158TKW0C5 / Phenytoin; ZH516LNZ10 / Piracetam
  •  go-up   go-down


95. Massimi L, Caldarelli M, D'Alessandris QG, Rollo M, Lauriola L, Giangaspero F, Di Rocco C: 12-year-old boy with multiple brain masses. Brain Pathol; 2010 May;20(3):679-82
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The occurrence of more than one brain tumor in a single patient is not new, resulting from RT- or CT-induced neoplasms, syndromes or casual association.
  • We report on the exceptional case of a 12-year-old boy harboring three different brain tumors with no definite correlation.
  • The first MRI showed a medulloblastoma with signs of infratentorial and supratentorial tumor spreading, including a small frontal mass.
  • Finally, the possible local recurrence of the original medulloblastoma was a pilocytic astrocytoma with post-radiation alterations.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cerebellar Neoplasms / pathology. Medulloblastoma / pathology. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20522094.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


96. Pascual-Castroviejo I, Pascual-Pascual SI, Viaño J, Carceller F, Gutierrez-Molina M, Morales C, Frutos-Martinez R: Posterior fossa tumors in children with neurofibromatosis type 1 (NF1). Childs Nerv Syst; 2010 Nov;26(11):1599-603
Genetic Alliance. consumer health - Neurofibromatosis type 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four of them had astrocytomas but only in one case was the tumour primarily cerebellar while the tumour was primarily of the brain stem with invasion of the adjacent regions of one or both cerebellar hemispheres in three patients.
  • The patient with primary cerebellar astrocytoma is apparently cured 7 years after the removal of the tumour.
  • The patients with the brain stem tumours extending to the cerebellum, showed a chronic slowly progressive cerebellar disease, but remain alive at age of more than 20 years (one was lost to follow-up).
  • Most of these tumours are histologically benign (low grade astrocytomas).
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / diagnosis. Astrocytoma / mortality. Astrocytoma / pathology. Astrocytoma / surgery. Brain Stem Neoplasms / diagnosis. Brain Stem Neoplasms / mortality. Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / surgery. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / mortality. Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / surgery. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Male. Medulloblastoma / diagnosis. Medulloblastoma / mortality. Medulloblastoma / pathology. Medulloblastoma / surgery. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Childs Nerv Syst. 2010 Nov;26(11):1491; author reply 1493 [20853110.001]
  • (PMID = 20464401.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


97. Lim BS, Park SQ, Chang UK, Kim MS: Spinal cord tanycytic ependymoma associated with neurofibromatosis type 2. J Clin Neurosci; 2010 Jul;17(7):922-4
Genetic Alliance. consumer health - Neurofibromatosis type 2.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tanycytic ependymoma is a rare subtype of ependymoma.
  • Reports of this tumor in neurofibromatosis type 2 (NF-2) are rare.
  • This rare morphology of tanycytic ependymoma could be misinterpreted as pilocytic astrocytoma or other tumor types that exhibit elongated cells.

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20403699.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


98. Liu Y, Tian RF, Li YM, Liu WP, Cao L, Yang XL, Cao WD, Zhang X: The expression of seven 14-3-3 isoforms in human meningioma. Brain Res; 2010 Jun 8;1336:98-102
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the previous study, the expression levels of all seven 14-3-3 isoforms were examined in astrocytoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Protein Isoforms / biosynthesis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20388496.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / Protein Isoforms
  •  go-up   go-down


99. De Armas R, Durand K, Guillaudeau A, Weinbreck N, Robert S, Moreau JJ, Caire F, Acosta G, Pebet M, Chaunavel A, Marin B, Labrousse F, Denizot Y: mRNA levels of enzymes and receptors implicated in arachidonic acid metabolism in gliomas. Clin Biochem; 2010 Jul;43(10-11):827-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mRNA levels of enzymes and receptors implicated in arachidonic acid metabolism in gliomas.
  • BACKGROUND: Gliomas are tumors of the central nervous system derived from glial cells.
  • Although a possible role for the eicosanoid cascade has been suggested in glioma tumorigenesis, the relationship between enzymes and receptors implicated in arachidonic acid metabolism, with histological tumor type has not yet been determined.
  • DESIGN AND METHODS: Quantitative real-time reverse transcription-polymerase chain reaction was performed to measure and compare transcript levels of enzymes and receptors implicated in both lipoxygenase and cyclooxygenase pathways between oligodendrogliomas, astrocytomas, glioblastomas and mixed oligoastrocytomas.
  • RESULTS: Arachidonic acid metabolism-related enzymes and receptor transcripts (i) were underexpressed in classical oligodendrogliomas compared to astrocytomas and/or glioblastomas, (ii) differed between astrocytomas and glioblastomas and (iii) had an intermediate expression in mixed oligoastrocytomas.
  • CONCLUSIONS: mRNA levels of enzymes and receptors implicated both in lipoxygenase and cyclooxygenase pathways differed significantly in gliomas according to the histological type.
  • [MeSH-major] Arachidonic Acid / metabolism. Central Nervous System Neoplasms / metabolism. Glioma / metabolism. Lipoxygenase / genetics. Prostaglandin-Endoperoxide Synthases / genetics. RNA, Messenger / analysis. Receptors, Prostaglandin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20382140.001).
  • [ISSN] 1873-2933
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Prostaglandin; 27YG812J1I / Arachidonic Acid; EC 1.13.11.12 / Lipoxygenase; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


100. Warnke PC: A 31-year-old woman with a transformed low-grade glioma. JAMA; 2010 Mar 10;303(10):967-76
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 31-year-old woman with a transformed low-grade glioma.
  • Low-grade gliomas in adults have an incidence of 0.8 to 1.2 per 100,000, and their causes are unknown.
  • Despite their histological classification as low-grade, they cannot be cured by any current treatment mode, and no class I evidence exists to guide initial treatment of these tumors.
  • The prognosis depends on age, World Health Organization (WHO) tumor grade, Karnofsky performance score, cytological type (oligodendroglioma vs astrocytoma), and, potentially, the extent of resection.
  • Low-grade tumors progress to high-grade gliomas with aggressive biological behavior at increasing frequency with advancing age.

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20159860.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement